# 6 - Approach to Patient
## Summary
text
### I. HORMONE CLASSIFICATION AND RECEPTOR DYNAMICS

| Feature | Amino Acid Derivatives / Peptides | Steroid Hormones / Vitamin Derivatives |
| :--- | :--- | :--- |
| **Solubility** | Water-soluble (usually) | Lipid-soluble |
| **Receptor Location** | <b style="color:red;">Cell-surface membrane receptors</b> | <b style="color:red;">Intracellular nuclear receptors</b> |
| **Storage** | Stored in **secretory granules** | Not stored; diffuse into circulation upon synthesis |
| **Examples** | Dopamine, Insulin, PTH, LH, TSH | Cortisol, Estrogen, Vitamin D, Retinoids |
| **Mechanism** | Signaling via GPCRs, Kinases | Alter gene transcription via DNA-binding |

* The <b style="color:red;">Endocrine System</b> involves hormones secreted internally to communicate broadly with distant organs, while the <b style="color:red;">Exocrine System</b> involves secretions into external lumens or the GI tract.
* Non-glandular organs with <b style="color:red;">Endocrine Function</b> include the heart (<b style="color:blue;">ANP</b>), kidneys (<b style="color:blue;">EPO, renin</b>), GI tract (<b style="color:blue;">GLP-1, Ghrelin</b>), and adipose tissue (<b style="color:blue;">Leptin</b>).
* <b style="color:red;">Glycoprotein Hormones</b> (TSH, FSH, LH, and hCG) share a common <b style="color:blue;">α-subunit</b>; specificity is determined by the distinct <b style="color:blue;">β-subunits</b>.
* Clinical cross-reactivity occurs in <b style="color:red;">Hyperthyroidism</b> when very high levels of <b style="color:blue;">hCG</b> stimulate the TSH receptor, leading to increased thyroid hormones and suppressed TSH.
* In the <b style="color:red;">Insulin-IGF Family</b>, tumor-produced <b style="color:blue;">IGF-2</b> can cause hypoglycemia by cross-reacting with insulin receptors.
* The <b style="color:red;">PTH-PTHrP System</b> involves two different proteins that bind the same <b style="color:blue;">PTH1 receptor</b> in bone and kidney, both causing hypercalcemia and hypophosphatemia.
* <b style="color:red;">Type 1 Nuclear Receptors</b> bind steroids (Glucocorticoids, Mineralocorticoids, Androgens, Estrogens, Progesterone).
* <b style="color:red;">Type 2 Nuclear Receptors</b> bind Thyroid hormone, Vitamin D, retinoic acid, and <b style="color:blue;">PPAR</b>.
* <b style="color:red;">11β-HSD (11β-hydroxysteroid dehydrogenase)</b> is an enzyme that protects the Mineralocorticoid Receptor (MR) by converting active <b style="color:blue;">cortisol</b> into inactive <b style="color:blue;">cortisone</b>.
* In <b style="color:red;">Cushing Syndrome</b>, high cortisol levels saturate 11β-HSD, leading to sodium retention, potassium loss, and hypertension via MR activation.
* <b style="color:red;">Estrogen Receptors (ER)</b> have relaxed ligand specificity, allowing them to bind environmental estrogens and drugs like <b style="color:blue;">Tamoxifen</b> or <b style="color:blue;">Raloxifene</b>.

### II. HORMONE SYNTHESIS, TRANSPORT, AND METABOLISM

| Hormone Property | Peptide Hormones | Steroid Hormones |
| :--- | :--- | :--- |
| **Precursor** | Prohormones (e.g., Proinsulin, POMC) | Cholesterol |
| **Secretion Trigger** | Releasing factors, Ca2+ influx, neural signals | Secretion rate is roughly equal to synthesis rate |
| **Transport** | Often circulate freely or with specific binders | Highly bound to serum carrier proteins |
| **Half-life** | Relatively short (minutes to hours) | Longer (hours to days; e.g., T4 is 7 days) |

* <b style="color:red;">Prohormone Processing</b> involves the cleavage of inactive precursors (e.g., <b style="color:blue;">Proinsulin</b>) into active hormones (e.g., <b style="color:blue;">Insulin</b>) and fragments like <b style="color:blue;">C-peptide</b>.
* <b style="color:red;">C-peptide</b> is cleaved from proinsulin in secretory granules and serves as a marker of endogenous insulin production.
* <b style="color:red;">POMC (Proopiomelanocortin)</b> is a large precursor polypeptide that is processed to yield <b style="color:blue;">ACTH</b> and other biologically active peptides.
* <b style="color:red;">StAR (Steroidogenic Acute Regulatory) Protein</b> is the rate-limiting factor that transports cholesterol into mitochondria for steroid synthesis.
* <b style="color:red;">Thyroid Hormone Half-life</b>: <b style="color:blue;">T4</b> has a half-life of 7 days (requires >1 month for steady state), whereas <b style="color:blue;">T3</b> has a half-life of 1 day (requires multiple daily doses).
* <b style="color:red;">Serum-Binding Proteins</b>, such as <b style="color:blue;">TBG</b> (for T4/T3) and <b style="color:blue;">CBG</b> (for Cortisol), provide a hormone reservoir and prevent rapid degradation.
* Only the <b style="color:red;">Unbound (Free) Hormone</b> is biologically active and available to interact with receptors.
* <b style="color:red;">Liver Disease</b> can decrease binding protein levels, while <b style="color:blue;">Estrogen</b> increases levels of Thyroxine-binding globulin (TBG).
* In women with <b style="color:red;">PCOS (Polycystic Ovary Syndrome)</b>, a decrease in <b style="color:blue;">SHBG</b> leads to increased unbound testosterone, contributing to hirsutism.
* <b style="color:red;">Pulsatile Secretion</b> is characteristic of many peptide hormones (ACTH, GH, LH); continuous administration of <b style="color:blue;">GnRH</b> actually causes pituitary desensitization.
* <b style="color:red;">Hormone Degradation</b> is essential for regulating local concentrations; <b style="color:blue;">Kidney failure</b> or <b style="color:blue;">Liver failure</b> can prolong hormone half-lives and cause accumulation.

### III. PHYSIOLOGIC FUNCTIONS AND FEEDBACK LOOPS

| Function Type | Key Regulators / Hormones | Clinical Significance |
| :--- | :--- | :--- |
| **Growth** | GH, IGF-1, Thyroid hormones | Deficiency leads to short stature; Sex steroids close epiphyses |
| **Homeostasis** | ADH, Insulin, PTH, Cortisol | Regulation of osmolality, glucose, calcium, and BP |
| **Reproduction** | GnRH, LH, FSH, Estrogen | Fertility, menstrual cycle, and pregnancy maintenance |

* <b style="color:red;">Negative Feedback</b> is the primary regulatory mechanism where the final product (e.g., T4 or Cortisol) inhibits the release of the stimulating hormones (TRH/TSH or CRH/ACTH).
* <b style="color:red;">Positive Feedback</b> occurs during the menstrual cycle when rising <b style="color:blue;">Estrogen</b> levels trigger the <b style="color:blue;">LH surge</b> required for ovulation.
* <b style="color:red;">Paracrine Regulation</b> occurs when a hormone acts on an adjacent cell (e.g., <b style="color:blue;">Somatostatin</b> inhibiting nearby insulin secretion).
* <b style="color:red;">Autocrine Regulation</b> occurs when a factor acts on the same cell that produced it (e.g., <b style="color:blue;">IGF-1</b> acting on chondrocytes).
* <b style="color:red;">Circadian Rhythms</b> dictate that <b style="color:blue;">ACTH and Cortisol</b> peak in the early morning and reach their lowest point (nadir) at midnight.
* <b style="color:red;">Stress Response</b> is mediated by the rapid release of catecholamines and the slower, sustained release of <b style="color:blue;">Cortisol</b>.

### IV. PATHOLOGIC MECHANISMS AND CLINICAL EVALUATION

| Pathology Type | Mechanism | Classic Examples |
| :--- | :--- | :--- |
| **Hormone Excess** | Neoplasia, Autoimmune, Iatrogenic | Cushing's, Graves' disease, MEN syndromes |
| **Hormone Deficiency** | Gland destruction (Autoimmune/Infarction) | Hashimoto's, Type 1 DM, Addison's disease |
| **Hormone Resistance** | Receptor or post-receptor defects | Type 2 DM, Leptin resistance in obesity |

* <b style="color:red;">MEN1 (Multiple Endocrine Neoplasia Type 1)</b> is characterized by the triad of parathyroid, pancreatic islet, and pituitary tumors due to <b style="color:blue;">Menin</b> inactivation.
* <b style="color:red;">MEN2</b> involves medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism due to <b style="color:blue;">RET protooncogene</b> mutations.
* <b style="color:red;">Immunoassays (ICMA/IRMA)</b> are the most important diagnostic tools for measuring hormone levels due to their high sensitivity (picomolar range).
* <b style="color:red;">24-Hour Urine Collections</b> are used to provide an integrated assessment of hormone production, bypassing the "noise" of pulsatile secretion (e.g., <b style="color:blue;">Urine Free Cortisol</b>).
* <b style="color:red;">Suppression Tests</b> are used to evaluate suspected hormone **hyperfunction** (e.g., using <b style="color:blue;">Dexamethasone</b> to suppress cortisol).
* <b style="color:red;">Stimulation Tests</b> are used to evaluate suspected hormone **hypofunction** (e.g., using <b style="color:blue;">ACTH</b> to stimulate the adrenal gland).
* In <b style="color:red;">Primary Glandular Failure</b>, the hormone level is low but the stimulating pituitary hormone (e.g., TSH, LH) is high due to lack of negative feedback.
* In <b style="color:red;">Secondary (Central) Failure</b>, both the stimulating pituitary hormone and the target gland hormone are low.
* <b style="color:red;">TSH</b> is considered the most sensitive first-line screening test for thyroid dysfunction.
* <b style="color:red;">Radiologic Imaging</b> should only be performed **after** a hormonal abnormality has been biochemically confirmed.
* Common Screening Recommendations: <b style="color:blue;">Type 2 DM</b> screen at age 45 (or earlier if high risk); <b style="color:blue;">Osteoporosis</b> screen in women >65 years.

### V. DIFFERENTIATING CLINICAL ENTITIES AND CONCEPTS

| Topic | Comparison 1 | Comparison 2 | Key Distinction |
| :--- | :--- | :--- | :--- |
| **Thyroid Axis** | <b style="color:red;">Primary Hypothyroidism</b> | <b style="color:red;">Secondary Hypothyroidism</b> | Primary has High TSH; Secondary has Low/Normal TSH with Low T4. |
| **Adrenal Axis** | <b style="color:red;">Cushing's Disease</b> | <b style="color:red;">Primary Adrenal Adenoma</b> | Cushing's (Pituitary) has High ACTH; Adenoma has Suppressed ACTH. |
| **Calcium Axis** | <b style="color:red;">Primary Hyperparathyroidism</b> | <b style="color:red;">Malignancy-associated Hypercalcemia</b> | PTH is High in Primary; PTH is Suppressed in Malignancy. |
| **Diabetes** | <b style="color:red;">Type 1 DM</b> | <b style="color:red;">Type 2 DM</b> | Type 1 is Hormone Deficiency; Type 2 is Hormone Resistance. |
| **Processing** | <b style="color:red;">Transcription/Translation</b> | <b style="color:red;">Posttranslational Processing</b> | Processing (e.g., C-peptide cleavage) happens after the protein is made. |
| **Measurement** | <b style="color:red;">Basal Testing</b> | <b style="color:red;">Dynamic Testing</b> | Dynamic tests (Stimulation/Suppression) distinguish borderline cases. |
| **Binding** | <b style="color:red;">Total Hormone</b> | <b style="color:red;">Free Hormone</b> | Only Free hormone is metabolically active and clinically relevant. |
| **Nuclear Receptors** | <b style="color:red;">Type 1 (Steroid)</b> | <b style="color:red;">Type 2 (Thyroid/Vit D)</b> | Type 1 starts in cytoplasm; Type 2 is usually already in the nucleus. |
| **Feedback** | <b style="color:red;">Negative Feedback</b> | <b style="color:red;">Positive Feedback</b> | Negative maintains stability; Positive (Estrogen/LH) triggers a specific event. |
| **MEN Syndromes** | <b style="color:red;">MEN 1</b> | <b style="color:red;">MEN 2</b> | MEN 1 = 3Ps (Pituitary, Pancreas, Parathyroid); MEN 2 = Medullary Thyroid, Pheo. |
| **Cortisol** | <b style="color:red;">Morning Cortisol</b> | <b style="color:red;">Midnight Cortisol</b> | Normal nadir is at midnight; loss of this nadir (High Midnight Cortisol) suggests Cushing's. |
| **Prohormones** | <b style="color:red;">Proinsulin</b> | <b style="color:red;">Preproinsulin</b> | Preproinsulin has a signal peptide for ER entry; Proinsulin has it removed. |
| **Medications** | <b style="color:red;">Salsalate</b> | <b style="color:red;">Amiodarone</b> | Salsalate displaces T4 from TBG; Amiodarone can interfere with TSH receptors/T4 conversion. |


## QA
text
### I. HORMONE CLASSIFICATION AND RECEPTOR DYNAMICS

1. What is the solubility of <b style="color:red;">Amino Acid Derivatives and Peptide Hormones</b>? | Water-soluble
2. What is the solubility of <b style="color:red;">Steroid Hormones and Vitamin Derivatives</b>? | Lipid-soluble
3. Where are the receptors for <b style="color:red;">Peptide Hormones</b> located? | Cell-surface membrane receptors
4. Where are the receptors for <b style="color:red;">Steroid Hormones</b> located? | Intracellular nuclear receptors
5. How are <b style="color:red;">Peptide Hormones</b> stored within the cell? | Secretory granules
6. How are <b style="color:red;">Steroid Hormones</b> released after synthesis? | Diffusion into circulation
7. What are examples of <b style="color:red;">Water-soluble Hormones</b>? (4) | Dopamine, Insulin, PTH, TSH
8. What are examples of <b style="color:red;">Lipid-soluble Hormones</b>? (4) | Cortisol, Estrogen, Vitamin D, Retinoids
9. What signaling mechanisms do <b style="color:red;">Peptide Hormones</b> use? | GPCRs and Kinases
10. What is the mechanism of action for <b style="color:red;">Nuclear Receptors</b>? | Alter gene transcription (DNA-binding)
11. Define the <b style="color:red;">Endocrine System</b>. | Internal secretion to distant organs
12. Define the <b style="color:red;">Exocrine System</b>. | Secretion into external lumens
13. What hormone is produced by the <b style="color:red;">Heart</b>? | Atrial Natriuretic Peptide (ANP)
14. What hormones are produced by the <b style="color:red;">Kidneys</b>? (2) | Erythropoietin and Renin
15. What hormones are produced by the <b style="color:red;">GI Tract</b>? (2) | GLP-1 and Ghrelin
16. What hormone is produced by <b style="color:red;">Adipose Tissue</b>? | Leptin
17. What common component is shared by <b style="color:red;">Glycoprotein Hormones</b> (TSH, FSH, LH, hCG)? | Alpha-subunit
18. What determines the functional specificity of <b style="color:red;">Glycoprotein Hormones</b>? | Beta-subunit
19. Why does <b style="color:red;">Hyperthyroidism</b> occur in states with very high hCG? | hCG stimulates TSH receptors
20. How can <b style="color:red;">IGF-2</b> produced by tumors cause hypoglycemia? | Cross-reacts with insulin receptors
21. Which receptor is shared by the <b style="color:red;">PTH-PTHrP System</b>? | PTH1 receptor
22. What are the metabolic effects of <b style="color:red;">PTH and PTHrP</b>? (2) | Hypercalcemia and Hypophosphatemia
23. What types of hormones bind to <b style="color:red;">Type 1 Nuclear Receptors</b>? | Steroid hormones
24. Name the hormones that bind to <b style="color:red;">Type 2 Nuclear Receptors</b>. (4) | Thyroid hormone, Vitamin D, Retinoic acid, PPAR
25. What is the function of the enzyme <b style="color:red;">11β-HSD</b>? | Converts cortisol to inactive cortisone
26. Which receptor is protected by <b style="color:red;">11β-HSD</b>? | Mineralocorticoid Receptor (MR)
27. Why does <b style="color:red;">Cushing Syndrome</b> cause hypertension and potassium loss? | High cortisol saturates 11β-HSD
28. What characteristic of <b style="color:red;">Estrogen Receptors</b> allows binding of Tamoxifen? | Relaxed ligand specificity

### II. HORMONE SYNTHESIS, TRANSPORT, AND METABOLISM

29. What are the precursors for <b style="color:red;">Peptide Hormones</b>? | Prohormones
30. What is the universal precursor for <b style="color:red;">Steroid Hormones</b>? | Cholesterol
31. What triggers the secretion of <b style="color:red;">Peptide Hormones</b>? (3) | Releasing factors, Ca2+, neural signals
32. What determines the secretion rate of <b style="color:red;">Steroid Hormones</b>? | Synthesis rate
33. How do <b style="color:red;">Peptide Hormones</b> usually circulate in the blood? | Freely (unbound)
34. How do <b style="color:red;">Steroid Hormones</b> travel through the blood? | Bound to serum carrier proteins
35. Compare the <b style="color:red;">Half-life</b> of Peptide vs Steroid hormones. | Peptides: Short; Steroids: Long
36. What is the half-life of <b style="color:red;">Thyroxine (T4)</b>? | 7 days
37. What process converts <b style="color:red;">Proinsulin</b> into active insulin? | Cleavage of C-peptide
38. What is the clinical significance of <b style="color:red;">C-peptide</b>? | Marker of endogenous insulin production
39. Which large precursor polypeptide is processed into <b style="color:red;">ACTH</b>? | POMC
40. What is the rate-limiting factor in <b style="color:red;">Steroid Synthesis</b>? | StAR protein
41. How long does it take for <b style="color:red;">Thyroxine (T4)</b> to reach steady state? | More than 1 month
42. What is the half-life of <b style="color:red;">Triiodothyronine (T3)</b>? | 1 day
43. Name the primary carrier protein for <b style="color:red;">Thyroid Hormones</b>. | Thyroxine-binding globulin (TBG)
44. Name the primary carrier protein for <b style="color:red;">Cortisol</b>. | Corticosteroid-binding globulin (CBG)
45. Which form of a hormone is <b style="color:red;">Biologically Active</b>? | Unbound (Free) hormone
46. How does <b style="color:red;">Liver Disease</b> affect hormone binding proteins? | Decreases levels
47. What effect does <b style="color:red;">Estrogen</b> have on TBG levels? | Increases levels
48. In <b style="color:red;">PCOS</b>, what happens to Sex Hormone-Binding Globulin (SHBG)? | Decreased levels
49. What is the clinical result of <b style="color:red;">Lowered SHBG</b> in PCOS? | Increased unbound testosterone (hirsutism)
50. What type of secretion is characteristic of <b style="color:red;">Peptide Hormones</b> (ACTH, GH, LH)? | Pulsatile secretion
51. What happens during <b style="color:red;">pituitary desensitization</b>? | Continuous GnRH administration
52. How does <b style="color:red;">Renal or Hepatic failure</b> affect hormone levels? | Prolonged half-life/accumulation

### III. PHYSIOLOGIC FUNCTIONS AND FEEDBACK LOOPS

53. Which hormones regulate <b style="color:red;">Growth</b>? (3) | GH, IGF-1, Thyroid hormones
54. What determines the <b style="color:red;">closure of epiphyses</b>? | Sex steroids
55. Name hormones essential for <b style="color:red;">Homeostasis</b>. (4) | ADH, Insulin, PTH, Cortisol
56. Which hormones regulate <b style="color:red;">Reproduction</b>? (4) | GnRH, LH, FSH, Estrogen
57. Define <b style="color:red;">Negative Feedback</b>. | Final product inhibits stimulating hormones
58. When does <b style="color:red;">Positive Feedback</b> occur in the menstrual cycle? | High estrogen triggers LH surge
59. Define <b style="color:red;">Paracrine Regulation</b>. | Hormone acts on adjacent cells
60. Define <b style="color:red;">Autocrine Regulation</b>. | Factor acts on secretion cell itself
61. What is the peak time for <b style="color:red;">ACTH and Cortisol</b>? | Early morning
62. What is the nadir (lowest point) for <b style="color:red;">Cortisol</b>? | Midnight
63. Which hormones mediate the <b style="color:red;">Rapid Stress Response</b>? | Catecholamines
64. Which hormone mediates the <b style="color:red;">Sustained Stress Response</b>? | Cortisol

### IV. PATHOLOGIC MECHANISMS AND CLINICAL EVALUATION

65. What are common causes of <b style="color:red;">Hormone Excess</b>? (3) | Neoplasia, Autoimmune, Iatrogenic
66. What are common causes of <b style="color:red;">Hormone Deficiency</b>? (2) | Autoimmune destruction or Infarction
67. Define <b style="color:red;">Hormone Resistance</b>. | Receptor or post-receptor defects
68. What is the triad of <b style="color:red;">MEN1</b>? | Parathyroid, Pancreatic islet, Pituitary tumors
69. What mutation causes <b style="color:red;">MEN1</b>? | Menin inactivation
70. What are the components of <b style="color:red;">MEN2</b>? (3) | Medullary thyroid, Pheochromocytoma, Hyperparathyroidism
71. What mutation causes <b style="color:red;">MEN2</b>? | RET protooncogene
72. What is the primary tool for <b style="color:red;">Hormone Measurement</b>? | Immunoassays (ICMA/IRMA)
73. Why are <b style="color:red;">24-Hour Urine Collections</b> used? | Assess integrated production/bypass pulsatility
74. When are <b style="color:red;">Suppression Tests</b> utilized? | Suspected hormone hyperfunction
75. When are <b style="color:red;">Stimulation Tests</b> utilized? | Suspected hormone hypofunction
76. In <b style="color:red;">Primary Glandular Failure</b>, what is the level of the stimulating hormone? | High (Elevated)
77. In <b style="color:red;">Secondary (Central) Failure</b>, what is the level of the stimulating hormone? | Low or inappropriately normal
78. What is the gold standard screening for <b style="color:red;">Thyroid Dysfunction</b>? | TSH (Thyroid-Stimulating Hormone)
79. When should <b style="color:red;">Radiologic Imaging</b> be performed in endocrinology? | After biochemical confirmation
80. What is the recommended screening age for <b style="color:red;">Type 2 Diabetes</b>? | Age 45
81. What is the recommended screening age for <b style="color:red;">Osteoporosis</b> in women? | Over 65 years

### V. DIFFERENTIATING CLINICAL ENTITIES AND CONCEPTS

82. Compare TSH levels in <b style="color:red;">Primary vs Secondary Hypothyroidism</b>. | Primary: High; Secondary: Low/Normal
83. Compare ACTH levels in <b style="color:red;">Cushing's Disease vs Adrenal Adenoma</b>. | Disease: High; Adenoma: Suppressed
84. Compare PTH levels in <b style="color:red;">Primary HPT vs Malignancy</b>. | Primary: High; Malignancy: Suppressed
85. Distinguish <b style="color:red;">Type 1 vs Type 2 DM</b> pathology. | Type 1: Deficiency; Type 2: Resistance
86. When does <b style="color:red;">C-peptide Cleavage</b> occur? | Posttranslational processing
87. What is the role of <b style="color:red;">Dynamic Testing</b>? | Distinguish borderline function cases
88. Why is <b style="color:red;">Free Hormone</b> measured instead of Total Hormone? | Only Free is metabolically active
89. Where do <b style="color:red;">Type 1 vs Type 2 Nuclear Receptors</b> reside initially? | Type 1: Cytoplasm; Type 2: Nucleus
90. Contrast <b style="color:red;">Negative vs Positive Feedback</b>. | Negative: Stability; Positive: Triggers events
91. Contrast the tumors of <b style="color:red;">MEN 1 vs MEN 2</b>. | MEN 1: 3Ps; MEN 2: MTC/Pheo
92. What does a high <b style="color:red;">Midnight Cortisol</b> suggest? | Cushing's Syndrome
93. What distinguishes <b style="color:red;">Preproinsulin</b> from Proinsulin? | Signal peptide for ER entry
94. How does <b style="color:red;">Salsalate</b> affect thyroid testing? | Displaces T4 from TBG
95. How does <b style="color:red;">Amiodarone</b> interfere with endocrine function? (2) | TSH receptor interference/T4 conversion blockage
96. Contrast the receptor location of <b style="color:red;">Catecholamines vs Cortisol</b>. | Catecholamines: Surface; Cortisol: Intracellular
97. What regulates the <b style="color:red;">osmolality</b> of blood? | ADH (Antidiuretic Hormone)
98. What is the precursor for <b style="color:red;">Vitamin D</b>? | Cholesterol derivative
99. Name the glycoprotein hormone used in <b style="color:red;">Pregnancy Tests</b>. | hCG
100. Define <b style="color:red;">Iatrogenic</b> hormone excess. | Caused by medical treatment/medications
101. What do <b style="color:red;">Kinases</b> do in peptide signaling? | Phosphorylate cellular proteins
102. What is <b style="color:red;">Menin</b>? | Tumor suppressor protein (MEN1)
103. Define <b style="color:red;">Pheochromocytoma</b>. | Catecholamine-secreting adrenal tumor (MEN2)
104. What does <b style="color:red;">Urine Free Cortisol</b> measure? | 24-hour integrated cortisol production
105. What is the stimulus for <b style="color:red;">Dexamethasone Suppression Test</b>? | Synthetic glucocorticoid
106. What is the stimulus for <b style="color:red;">ACTH Stimulation Test</b>? | Cosyntropin
107. Which gland fails in <b style="color:red;">Addison's Disease</b>? | Adrenal gland
108. Which gland fails in <b style="color:red;">Hashimoto's</b>? | Thyroid gland
109. What happens to FSH in <b style="color:red;">Primary Ovarian Failure</b>? | Becomes elevated
110. What metabolic condition is caused by <b style="color:red;">PTH1 receptor</b> activation? | Hypercalcemia
111. What is the role of <b style="color:red;">PPAR</b> receptors? | Metabolic regulation/Gene transcription
112. How does <b style="color:red;">Raloxifene</b> act on estrogen receptors? | Selective modulation
113. Define the <b style="color:red;">Circadian Rhythm</b> nadir. | The lowest concentration point
114. What constitutes the <b style="color:red;">adrenal axis</b> components? | CRH, ACTH, Cortisol
115. What constitutes the <b style="color:red;">thyroid axis</b> components? | TRH, TSH, T4/T3
116. Contrast prohormone <b style="color:red;">Storage</b> vs synthesis. | Stored in granules before secretion
117. What does the <b style="color:red;">StAR</b> protein transport? | Cholesterol into mitochondria
118. What defines <b style="color:red;">Hirsutism</b> in PCOS? | Excessive terminal hair growth
119. What is the clinical name for <b style="color:red;">Low T4 and High TSH</b>? | Primary Hypothyroidism
120. What is the clinical name for <b style="color:red;">Low T4 and Low TSH</b>? | Secondary Hypothyroidism


# 7
## Summary
text
### I. EPIDEMIOLOGY AND CLASSIFICATION OF DIABETES MELLITUS

* **Global Burden**: <b style="color:red;">Diabetes</b> is a leading worldwide health problem; 55% of individuals with diabetes reside in the <b style="color:red;">Southeast Asia and Western Pacific Regions</b>.
* **HbA1C Target**: For Filipino patients, the <b style="color:red;">target glycemic average</b> is an <b style="color:red;">HbA1C of 7%</b> (estimated average glucose of 154 mg/dL).
* **Type 1 Diabetes Mellitus (T1DM)**: Characterized by <b style="color:red;">complete or near total insulin deficiency</b> due to an autoimmune attack on pancreatic beta cells; frequently associated with HLA-DR3/DR4 genes.
* **Type 2 Diabetes Mellitus (T2DM)**: Characterized by a triad of <b style="color:red;">insulin resistance</b>, <b style="color:red;">impaired insulin secretion</b>, and <b style="color:red;">increased hepatic glucose production</b>.
* **Gestational Diabetes Mellitus (GDM)**: Defined as <b style="color:red;">glucose intolerance</b> first developing during the <i>second or third trimester</i> of pregnancy.
* **Overt Diabetes in Pregnancy**: Diabetes diagnosed during the <b style="color:red;">initial prenatal visit</b> (first trimester) is classified as preexisting pregestational diabetes, not GDM.
* **GDM Future risk**: Women with GDM have a <b style="color:red;">35-60% risk</b> of developing DM within 10-20 years and require screening at least <b style="color:red;">every 3 years</b> lifelong.
* **Maturity-Onset Diabetes of the Young (MODY)**: A form of monogenic diabetes characterized by <b style="color:red;">autosomal dominant inheritance</b>, early onset (usually <25 years), and impaired insulin secretion.
* **Ketosis-Prone T2DM**: Seen in African American or Asian heritage; patients present with ketoacidosis (typical of T1) but <b style="color:red;">do not require long-term insulin</b> and can eventually be managed with oral agents.
* **Latent Autoimmune Diabetes in Adults (LADA)**: Also called <b style="color:red;">autoimmune diabetes of adults</b>; presents phenotypically like T2DM but possesses islet antibodies and progresses to insulin dependence.
* **Fulminant Diabetes**: A form of <b style="color:red;">acute-onset Type 1 DM</b> (noted in Japan) potentially triggered by viral infections.

### II. DIAGNOSTIC CRITERIA AND SCREENING

* **Fasting Plasma Glucose (FPG)**: Normal is <b style="color:red;"><100 mg/dL</b>; Diabetes is <b style="color:red;">≥126 mg/dL</b>.
* **HbA1C Levels**: Normal is <5.7%; <b style="color:red;">Prediabetes</b> is 5.7%-6.4%; <b style="color:red;">Diabetes</b> is ≥6.5%.
* **Oral Glucose Tolerance Test (OGTT)**: Normal 2-h PG is <140 mg/dL; <b style="color:red;">Impaired Glucose Tolerance (IGT)</b> is 140-199 mg/dL; <b style="color:red;">Diabetes</b> is ≥200 mg/dL.
* **Random Plasma Glucose**: <b style="color:red;">≥200 mg/dL</b> in a patient with classic symptoms (polyuria, polydipsia, weight loss) is diagnostic of Diabetes.
* **Confirmatory Testing**: Unless there is clear clinical diagnosis (e.g., hyperglycemic crisis), abnormal screening tests must be <b style="color:red;">repeated</b> to confirm diagnosis.
* **General Screening Recommendation**: Screen all individuals starting at <b style="color:red;">age 45 every 3 years</b>; screen earlier if BMI >25 kg/m² (or ethnic equivalent) plus one additional risk factor.
* **Triple Catabolic Symptoms**: The presumptive symptoms of DM are <b style="color:red;">Polydipsia</b> (thirst), <b style="color:red;">Polyuria</b> (excessive urine), and <b style="color:red;">unintentional weight loss</b>.

### III. PATHOGENESIS OF TYPE 1 AND TYPE 2 DM

* **T1DM Genetic Risk**: The <b style="color:red;">HLA region on Chromosome 6</b> (MHC Class II) is the major susceptibility locus, specifically <b style="color:red;">DR3 and/or DR4 haplotypes</b>.
* **T1DM Clinical Presentation**: Often has an <b style="color:red;">acute, dramatic onset</b>; 25-50% present with Diabetic Ketoacidosis (DKA) at initial diagnosis.
* **T1DM Autoantibodies**: Presence of <b style="color:red;">GAD-65, ICA-512 (IA-2), and Zinc transporter (ZnT-8)</b> antibodies helps document the autoimmune process.
* **Honey-moon Phase**: In T1DM, a <b style="color:red;">transient period</b> of low insulin requirement or insulin independence may occur shortly after diagnosis before absolute deficiency occurs.
* **T1DM Environmental Triggers**: Proposed triggers for autoimmunity include <b style="color:red;">Coxsackie virus</b>, rubella, bovine milk proteins, and Vitamin D deficiency.
* **T2DM Postreceptor Defects**: The precise molecular mechanism of insulin resistance involves <b style="color:red;">"postreceptor" defects</b> in insulin-regulated phosphorylation/dephosphorylation.
* **T2DM Hepatic Glucose**: Insulin resistance in the liver results in a <b style="color:red;">failure to suppress gluconeogenesis</b>, leading to fasting hyperglycemia.
* **T2DM Adipose Tissue**: Resistance leads to <b style="color:red;">increased lipolysis</b> and free fatty acid (FFA) flux, which predisposes to <b style="color:red;">NAFLD/steatosis</b> and abnormal liver function tests.
* **Ominous Octet / Egregious Eleven**: Pathogenic models for T2DM that include defects in the <b style="color:red;">pancreas (alpha/beta cells)</b>, gut (incretin effect), kidneys (glucose reabsorption), brain, liver, muscle, and adipose tissue.
* **Asian Phenotype (T2DM)**: Asians often have a <b style="color:red;">lower BMI</b>, higher propensity for <b style="color:red;">visceral obesity</b>, and reduced pancreatic beta-cell mass compared to Western populations.

### IV. PHARMACOLOGIC MANAGEMENT: INSULIN THERAPY

* **Basal Insulin**: Essential for regulating <b style="color:red;">glycogen breakdown and gluconeogenesis</b>; include NPH, Glargine, Detemir, and Degludec.
* **Prandial (Mealtime) Insulin**: Required for <b style="color:red;">postprandial glucose utilization</b>; rapid-acting analogs (Lispro, Aspart, Glulisine) or Regular insulin.
* **Rapid-acting Insulin Analogs**: Onset in <b style="color:red;"> less than 15 minutes</b> ; peak in 0.5-1.5 hours; duration 3-4 hours; should be given <b style="color:red;">&lt10 mins before or after</b> a meal.
* **Short-acting (Regular) Insulin**: Onset in 0.5-1.0 hour; peak in 2-3 hours; should be given <b style="color:red;">30-45 mins before</b> a meal.
* **Intermediate-acting (NPH) Insulin**: Onset in 1-4 hours; peak in <b style="color:red;">6-10 hours</b>; duration 10-16 hours.
* **Long-acting Insulin (Glargine/Degludec)**: Provide <b style="color:red;">peakless</b> coverage; Degludec has a duration of action of <b style="color:red;">30 hours</b>.
* **Total Daily Dose (TDD)**: Estimated at <b style="color:red;">0.5-1.0 U/kg/day</b>; typically split 50% basal and 50% bolus (prandial).
* **Dawn Phenomenon**: Early morning hyperglycemia due to <b style="color:red;">nocturnal growth hormone and cortisol</b> secretion; requires adjustment of basal insulin.
* **Premixed Insulins**: Usually administered <b style="color:red;">twice daily</b>; the smaller number in the ratio represents the short-acting component (e.g., 70/30).
* **Continuous Subcutaneous Insulin Infusion (CSII)**: Insulin pumps use <b style="color:red;">rapid-acting insulin only</b> to provide both basal and bolus doses; highly effective for T1DM.

### V. PHARMACOLOGIC MANAGEMENT: NON-INSULIN AGENTS

* **Metformin (Biguanide)**: The <b style="color:red;">preferred initial agent</b> for T2DM; reduces hepatic glucose production; weight neutral; most common side effect is <b style="color:red;">GI upset</b>.
* **Metformin Contraindication**: Should be stopped if <b style="color:red;">eGFR &lt30 mL/min/1.73m²</b> due to the risk of <b style="color:red;">lactic acidosis</b>.
* **Sulfonylureas (SU)**: Insulin secretagogues (e.g., Glimepiride); high HbA1C lowering efficacy but carry <b style="color:red;">high risk of hypoglycemia</b> and weight gain.
* **TZDs (Thiazolidinediones)**: Insulin sensitizers (e.g., Pioglitazone); <b style="color:red;">no hypoglycemia</b> risk; side effects include weight gain, <b style="color:red;">fluid retention/HF risk</b>, and bone fractures.
* **DPP-4 Inhibitors (Gliptins)**: Enhance incretin action; <b style="color:red;">weight neutral</b> with no hypoglycemia; Linagliptin and Teneligliptin do not require dose adjustment for renal failure.
* **SGLT2 Inhibitors (-flozins)**: Promote <b style="color:red;">urinary glucose excretion</b>; offer significant <b style="color:red;">CV and renal benefits</b>; risk of euglycemic DKA and genital mycotic infections.
* **GLP-1 Receptor Agonists**: Injectables (e.g., Liraglutide, Semaglutide); provide <b style="color:red;">high efficacy for weight loss</b> and CV benefit; most common side effect is nausea.

### VI. ACUTE COMPLICATIONS: DKA AND HHS

* **Diabetic Ketoacidosis (DKA) Triad**: <b style="color:red;">Hyperglycemia (>250 mg/dL)</b>, <b style="color:red;">Metabolic Acidosis (pH <7.3, HCO₃ <18)</b>, and <b style="color:red;">Increased Ketones</b>; primary ketone is <i>beta-hydroxybutyrate</i>.
* **DKA Pathophysiology**: Absolute or relative <b style="color:red;">insulin deficiency</b> plus excess counterregulatory hormones leading to massive lipolysis and ketogenesis.
* **Hyperosmolar Hyperglycemic State (HHS) Hallmark**: <b style="color:red;">Severe Hyperglycemia (>1000 mg/dL)</b>, <b style="color:red;">Hyperosmolality (>300 mOsm/L)</b>, and profound <b style="color:red;">dehydration</b> without significant acidosis/ketones.
* **HHS Epidemiology**: Most commonly presents in <b style="color:red;">elderly T2DM patients</b> with diminished oral intake or acute stressors (MI, sepsis).
* **Euglycemic DKA**: Ketosis occurring with glucose levels <b style="color:red;">200-250 mg/dL</b>; most commonly associated with <b style="color:red;">SGLT2 inhibitor</b> use.
* **DKA/HHS Fluid Management**: Initial therapy is <b style="color:red;">0.9% Normal Saline (1-3 L over 2-3 h)</b>; switch to 0.45% saline if Na+ >150 mEq/L.
* **Insulin in Crisis**: IV bolus of <b style="color:red;">0.1 unit/kg</b> followed by an infusion of 0.1 unit/kg/hr; add dextrose to fluids once glucose reaches <b style="color:red;">200-250 mg/dL</b>.

### VII. CHRONIC MICROVASCULAR COMPLICATIONS

* **Diabetic Retinopathy**: Leading cause of new <b style="color:red;">blindness</b> in adults 20-74; features include microaneurysms, hemorrhages, <b style="color:red;">cotton-wool spots</b>, and neovascularization.
* **Retinopathy Screening**: Screen T2DM at <b style="color:red;">diagnosis</b>; T1DM <b style="color:red;">5 years after onset</b>; then annually.
* **Diabetic Nephropathy**: Leading cause of <b style="color:red;">End-Stage Renal Disease (ESRD)</b>; hallmark pathologic lesion is the <b style="color:red;">Kimmelstiel-Wilson (KW)</b> nodule.
* **Nephropathy Screening**: Measured by <b style="color:red;">Estimated GFR (eGFR) and Urinary Albumin-to-Creatinine Ratio (UACR)</b>; abnormal UACR is <b style="color:red;">≥30 mg/g</b> (confirmed by 2 of 3 specimens).
* **Nephropathy Management**: First-line for HTN in DM with albuminuria are <b style="color:red;">ACE Inhibitors or ARBs</b> (never used in combination or during pregnancy).
* **Symmetric Peripheral Polyneuropathy**: The <b style="color:red;">most common</b> form of neuropathy; presents as sensory loss in a <b style="color:red;">"stocking-glove"</b> distribution, often symptomatic at <b style="color:red;">night</b>.
* **Loss of Protective Sensation (LOPS)**: Screened using a <b style="color:red;">10-g monofilament</b>; lack of feeling in 4 or more points indicates neuropathy and high risk for ulcers/amputation.
* **Cardiac Autonomic Neuropathy (CAN)**: Independent risk factor for CV mortality; presents as <b style="color:red;">resting tachycardia</b> or orthostatic hypotension.
* **Gastrointestinal Autonomic Neuropathy**: Includes <b style="color:red;">gastroparesis</b> (anorexia, nausea, early satiety) and <b style="color:red;">diabetic enteropathy</b> (diarrhea/constipation).

### VIII. CHRONIC MACROVASCULAR AND SYSTEMIC MANAGEMENT

* **Aspirin Therapy**: Used for <b style="color:red;">secondary prevention</b> in DM with history of CVD; use <b style="color:red;">Clopidogrel</b> if aspirin allergy is present.
* **Statin Therapy**: Recommended for all DM patients <b style="color:red;">over age 40</b> or those with overt CVD regardless of cholesterol levels.
* **Foot Care Essentials**: Clean feet daily with warm water; <b style="color:red;">never soak</b>; moisturize (not between toes); cut nails to the shape of the toe; always wear shoes/slippers.
* **Blood Pressure Targets**: Generally <b style="color:red;">&lt140/80 mmHg</b>; <130/80 mmHg for younger patients with higher risk.
* **Lipid Targets**: LDL <b style="color:red;">&lt100 mg/dL</b> (<70 mg/dL for those with overt CVD); Triglycerides <b style="color:red;">&lt150 mg/dL</b>.

### IX. COMPARATIVE SUMMARY OF CLINICAL ENTITIES

| Feature | Type 1 DM | Type 2 DM |
| :--- | :--- | :--- |
| **Primary Defect** | Autoimmune Beta-cell destruction | Insulin Resistance + Beta-cell exhaustion |
| **Typical Onset Age** | < 20 years (but can be any age) | > 45 years (but shifting younger) |
| **Body Habitus** | Lean | Obese/Overweight |
| **Insulin Levels** | Low or Undetectable | High (early), Low (late) |
| **Acute Complication** | Diabetic Ketoacidosis (DKA) | Hyperosmolar Hyperglycemic State (HHS) |
| **HLA Association** | Strongly associated (DR3/DR4) | Not associated |

| Feature | Diabetic Ketoacidosis (DKA) | Hyperosmolar Hyperglycemic State (HHS) |
| :--- | :--- | :--- |
| **Main Patient Pop** | Type 1 DM (Younger) | Type 2 DM (Elderly) |
| **Glucose Level** | > 250 mg/dL | > 600 - 1000+ mg/dL |
| **Dehydration** | Moderate | Severe/Profound |
| **Ketones** | Markedly Positive | Absent or trace |
| **Acid-Base Status** | Metabolic Acidosis (pH < 7.3) | Normal or slightly low pH (> 7.3) |
| **Serum Bicarbonate** | Low (< 18 mEq/L) | Relatively Normal (> 18 mEq/L) |

| Insulin Type | Generic Examples | Onset | Peak | Goal |
| :--- | :--- | :--- | :--- | :--- |
| **Rapid-acting** | Aspart, Lispro, Glulisine | < 15 min | 0.5 - 1.5 hr | Mealtime coverage/bolus |
| **Short-acting** | Regular | 0.5 - 1 hr | 2 - 3 hr | Mealtime coverage/bolus |
| **Intermediate** | NPH | 1 - 4 hr | 6 - 10 hr | Basal coverage (twice daily) |
| **Long-acting** | Glargine, Detemir, Degludec | 1 - 4 hr | Peakless | 24-hr Basal coverage |

| Neuropathy Screen | Significance | Abnormal Finding |
| :--- | :--- | :--- |
| **10-g Monofilament** | Touch/Pressure Sensation | < 4/10 sites felt (Neuropathy) |
| **128-Hz Tuning Fork** | Vibration Sensation | Diminished/Absent vibration sense |
| **Ankle Reflexes** | Nerve Function | Absent Achilles reflex |
| **Visual Inspection** | Structural integrity | Deformities, calluses, ulcers |


## QA
text
text
### I. EPIDEMIOLOGY AND CLASSIFICATION OF DIABETES MELLITUS

1. Where do 55% of individuals with <b style="color:red;">Diabetes</b> reside? | Southeast Asia and Western Pacific
2. What is the <b style="color:red;">target HbA1C</b> for Filipino patients? | 7%
3. What is the <b style="color:red;">estimated average glucose</b> corresponding to an HbA1C of 7%? | 154 mg/dL
4. What is the primary characteristic of <b style="color:red;">Type 1 Diabetes Mellitus</b>? | Complete or near total insulin deficiency
5. What is the cause of beta cell destruction in <b style="color:red;">Type 1 DM</b>? | Autoimmune attack
6. Which genes are frequently associated with <b style="color:red;">Type 1 DM</b>? | HLA-DR3/DR4
7. What are the triad characteristics of <b style="color:red;">Type 2 Diabetes Mellitus</b>? (3) | 1) Insulin resistance <br>2) Impaired insulin secretion <br>3) Increased hepatic glucose production
8. What is the definition of <b style="color:red;">Gestational Diabetes Mellitus</b>? | Glucose intolerance first developing during 2nd or 3rd trimester
9. How is diabetes diagnosed at the <b style="color:red;">initial prenatal visit</b> classified? | Preexisting pregestational diabetes
10. What is the 10-20 year <b style="color:red;">future risk</b> of DM for women with GDM? | 35-60%
11. How often should women with a history of <b style="color:red;">GDM</b> be screened? | Every 3 years lifelong
12. What are the features of <b style="color:red;">Maturity-Onset Diabetes of the Young (MODY)</b>? (3) | 1) Autosomal dominant inheritance <br>2) Early onset (<25 years) <br>3) Impaired insulin secretion
13. Which heritage is most associated with <b style="color:red;">Ketosis-Prone T2DM</b>? | African American or Asian
14. Do patients with <b style="color:red;">Ketosis-Prone T2DM</b> require long-term insulin? | No
15. What is the phenotypic presentation of <b style="color:red;">Latent Autoimmune Diabetes in Adults (LADA)</b>? | Phenotypically like T2DM
16. What does <b style="color:red;">LADA</b> possess that leads to insulin dependence? | Islet antibodies
17. What is <b style="color:red;">Fulminant Diabetes</b>? | Acute-onset Type 1 DM
18. What is a potential trigger for <b style="color:red;">Fulminant Diabetes</b>? | Viral infections

### II. DIAGNOSTIC CRITERIA AND SCREENING

19. What is a <b style="color:red;">normal Fasting Plasma Glucose (FPG)</b> level? | < 100 mg/dL
20. What <b style="color:red;">Fasting Plasma Glucose (FPG)</b> level is diagnostic of Diabetes? | ≥ 126 mg/dL
21. What is a <b style="color:red;">normal HbA1C</b> level? | < 5.7%
22. What <b style="color:red;">HbA1C range</b> is diagnostic of Prediabetes? | 5.7%-6.4%
23. What <b style="color:red;">HbA1C level</b> is diagnostic of Diabetes? | ≥ 6.5%
24. What is a <b style="color:red;">normal 2-h PG</b> during an OGTT? | < 140 mg/dL
25. What <b style="color:red;">2-h OGTT range</b> defines Impaired Glucose Tolerance (IGT)? | 140-199 mg/dL
26. What <b style="color:red;">2-h OGTT level</b> is diagnostic of Diabetes? | ≥ 200 mg/dL
27. What <b style="color:red;">Random Plasma Glucose</b> level is diagnostic with classic symptoms? | ≥ 200 mg/dL
28. What are the <b style="color:red;">Triple Catabolic Symptoms</b> of DM? (3) | 1) Polydipsia <br>2) Polyuria <br>3) Unintentional weight loss
29. How must abnormal screening tests be handled if there is no hyperglycemic crisis? | They must be repeated
30. What is the <b style="color:red;">general screening recommendation</b> for age and frequency? | Age 45 every 3 years
31. When should screening occur earlier than age 45? (2) | 1) BMI > 25 kg/m² <br>2) One additional risk factor

### III. PATHOGENESIS OF TYPE 1 AND TYPE 2 DM

32. What is the major susceptibility locus for <b style="color:red;">T1DM genetic risk</b>? | HLA region on Chromosome 6
33. Which specific <b style="color:red;">HLA haplotypes</b> are linked to T1DM? | DR3 and/or DR4
34. What percentage of <b style="color:red;">T1DM patients</b> present with DKA at diagnosis? | 25-50%
35. Name the <b style="color:red;">autoantibodies</b> used to document T1DM. (3) | GAD-65, ICA-512 (IA-2), and ZnT-8
36. What is the <b style="color:red;">Honey-moon Phase</b> in T1DM? | Transient period of insulin independence
37. Name the proposed <b style="color:red;">environmental triggers</b> for T1DM. (4) | Coxsackie virus, rubella, bovine milk, Vitamin D deficiency
38. What molecular mechanism is involved in <b style="color:red;">T2DM insulin resistance</b>? | Postreceptor defects
39. Insulin resistance in the <b style="color:red;">liver</b> leads to what failure? | Failure to suppress gluconeogenesis
40. What is the result of <b style="color:red;">increased lipolysis</b> in T2DM adipose tissue? | NAFLD/steatosis
41. What pathogenic models describe the multiple defects in T2DM? | Ominous Octet / Egregious Eleven
42. Name organs involved in the <b style="color:red;">Ominous Octet</b>. (5) | Pancreas, gut, kidneys, liver, muscle
43. Describe the <b style="color:red;">Asian Phenotype</b> of T2DM compared to Westerners. (3) | 1) Lower BMI <br>2) Visceral obesity <br>3) Reduced beta-cell mass

### IV. PHARMACOLOGIC MANAGEMENT: INSULIN THERAPY

44. What processes does <b style="color:red;">Basal Insulin</b> regulate? | Glycogen breakdown and gluconeogenesis
45. Name examples of <b style="color:red;">Basal Insulin</b>. (4) | NPH, Glargine, Detemir, Degludec
46. What is the purpose of <b style="color:red;">Prandial Insulin</b>? | Postprandial glucose utilization
47. Name <b style="color:red;">Rapid-acting</b> Insulin analogs. (3) | Lispro, Aspart, Glulisine
48. What is the <b style="color:red;">onset</b> of Rapid-acting Insulin analogs? | < 15 minutes
49. What is the <b style="color:red;">peak</b> of Rapid-acting Insulin analogs? | 0.5-1.5 hours
50. When should <b style="color:red;">Rapid-acting Insulin</b> be administered? | < 10 mins before/after meal
51. What is the <b style="color:red;">onset</b> of Short-acting (Regular) Insulin? | 0.5-1.0 hour
52. When should <b style="color:red;">Regular Insulin</b> be given? | 30-45 mins before meal
53. What is the <b style="color:red;">peak</b> of Intermediate-acting (NPH) Insulin? | 6-10 hours
54. What is the <b style="color:red;">duration</b> of NPH? | 10-16 hours
55. What is the hallmark feature of <b style="color:red;">Long-acting Insulin</b>? | Peakless coverage
56. What is the <b style="color:red;">duration of action</b> of Degludec? | 30 hours
57. What is the estimated <b style="color:red;">Total Daily Dose (TDD)</b> of insulin? | 0.5-1.0 U/kg/day
58. What is the typical <b style="color:red;">split</b> for TDD? | 50% basal and 50% bolus
59. What causes the <b style="color:red;">Dawn Phenomenon</b>? | Nocturnal growth hormone and cortisol
60. How many times daily are <b style="color:red;">Premixed Insulins</b> usually given? | Twice daily
61. What does the smaller number in a <b style="color:red;">premixed ratio</b> represent? | Short-acting component
62. What type of insulin is used in <b style="color:red;">CSII (Insulin pumps)</b>? | Rapid-acting insulin only

### V. PHARMACOLOGIC MANAGEMENT: NON-INSULIN AGENTS

63. What is the <b style="color:red;">preferred initial agent</b> for T2DM? | Metformin
64. What is the mechanism of <b style="color:red;">Metformin</b>? | Reduces hepatic glucose production
65. What is the most common side effect of <b style="color:red;">Metformin</b>? | GI upset
66. At what <b style="color:red;">eGFR</b> level must Metformin be stopped? | < 30 mL/min/1.73m²
67. What is the severe risk of <b style="color:red;">Metformin</b> in renal failure? | Lactic acidosis
68. What is the mechanism of <b style="color:red;">Sulfonylureas (SU)</b>? | Insulin secretagogues
69. What are the primary risks of <b style="color:red;">Sulfonylureas</b>? (2) | 1) Hypoglycemia <br>2) Weight gain
70. What is the mechanism of <b style="color:red;">TZDs (Pioglitazone)</b>? | Insulin sensitizers
71. Name the side effects of <b style="color:red;">TZDs</b>. (3) | Weight gain, fluid retention, fractures
72. Which <b style="color:red;">DPP-4 Inhibitors</b> do not require renal dose adjustment? | Linagliptin and Teneligliptin
73. What is the mechanism of <b style="color:red;">SGLT2 Inhibitors</b>? | Promote urinary glucose excretion
74. Name the benefits of <b style="color:red;">SGLT2 Inhibitors (-flozins)</b>. | CV and renal benefits
75. What are the risks of <b style="color:red;">SGLT2 Inhibitors</b>? (2) | Euglycemic DKA and genital infections
76. What are the benefits of <b style="color:red;">GLP-1 Receptor Agonists</b>? | Weight loss and CV benefit
77. What is the common side effect of <b style="color:red;">GLP-1 Agonists</b>? | Nausea

### VI. ACUTE COMPLICATIONS: DKA AND HHS

78. What is the <b style="color:red;">DKA Triad</b>? (3) | 1) Hyperglycemia (>250) <br>2) Acidosis (pH <7.3) <br>3) Ketones
79. What is the primary ketone in <b style="color:red;">DKA</b>? | Beta-hydroxybutyrate
80. What causes massive lipolysis in <b style="color:red;">DKA</b>? | Insulin deficiency + counterregulatory hormones
81. What is the hallmark of <b style="color:red;">HHS</b>? | Hyperglycemia >1000 and Hyperosmolality
82. Does <b style="color:red;">HHS</b> present with significant acidosis? | No
83. Which patient population most commonly presents with <b style="color:red;">HHS</b>? | Elderly T2DM patients
84. What glucose level is seen in <b style="color:red;">Euglycemic DKA</b>? | < 200-250 mg/dL
85. Which drug class is associated with <b style="color:red;">Euglycemic DKA</b>? | SGLT2 inhibitors
86. What is the <b style="color:red;">initial fluid therapy</b> for DKA/HHS? | 0.9% Normal Saline (1-3 L)
87. When is fluid switched to <b style="color:red;">0.45% saline</b> in DKA? | If Na+ > 150 mEq/L
88. What is the <b style="color:red;">initial insulin dose</b> in DKA crisis? | 0.1 unit/kg bolus
89. When should <b style="color:red;">dextrose</b> be added to DKA fluids? | Glucose < 200-250 mg/dL

### VII. CHRONIC MICROVASCULAR COMPLICATIONS

90. What is the leading cause of new <b style="color:red;">blindness</b> in adults? | Diabetic Retinopathy
91. Name clinical features of <b style="color:red;">Diabetic Retinopathy</b>. (3) | Microaneurysms, hemorrhages, cotton-wool spots
92. When is the first <b style="color:red;">retinopathy screening</b> for T2DM? | At diagnosis
93. When is the first <b style="color:red;">retinopathy screening</b> for T1DM? | 5 years after onset
94. What is the leading cause of <b style="color:red;">ESRD</b>? | Diabetic Nephropathy
95. What is the hallmark pathologic lesion of <b style="color:red;">Diabetic Nephropathy</b>? | Kimmelstiel-Wilson (KW) nodule
96. How is <b style="color:red;">Nephropathy</b> screened? (2) | eGFR and UACR
97. What <b style="color:red;">UACR level</b> is considered abnormal? | ≥ 30 mg/g
98. What are the first-line agents for <b style="color:red;">HTN with DM albuminuria</b>? | ACE Inhibitors or ARBs
99. True or False: <b style="color:red;">ACE Inhibitors and ARBs</b> can be used together. | False
100. What is the most common form of <b style="color:red;">diabetic neuropathy</b>? | Symmetric Peripheral Polyneuropathy
101. Describe the sensory loss distribution in <b style="color:red;">diabetic neuropathy</b>. | Stocking-glove distribution
102. When are <b style="color:red;">neuropathy symptoms</b> often worse? | At night
103. What tool is used to screen for <b style="color:red;">Loss of Protective Sensation (LOPS)</b>? | 10-g monofilament
104. How many points not felt on <b style="color:red;">monofilament test</b> indicate high risk? | 4 or more points
105. What are signs of <b style="color:red;">Cardiac Autonomic Neuropathy (CAN)</b>? (2) | Resting tachycardia, orthostatic hypotension
106. Name symptoms of <b style="color:red;">Gastroparesis</b>. (3) | Anorexia, nausea, early satiety

### VIII. CHRONIC MACROVASCULAR AND SYSTEMIC MANAGEMENT

107. When is <b style="color:red;">Aspirin</b> used in DM management? | Secondary prevention of CVD
108. What is the alternative if a patient has an <b style="color:red;">aspirin allergy</b>? | Clopidogrel
109. Who should receive <b style="color:red;">Statin Therapy</b>? | All DM over age 40
110. List <b style="color:red;">Foot Care Essentials</b>. (4) | 1) Clean daily <br>2) Never soak <br>3) Moisturize <br>4) Always wear shoes
111. What is the general <b style="color:red;">Blood Pressure Target</b> for DM? | < 140/80 mmHg
112. What is the <b style="color:red;">LDL Target</b> for DM without overt CVD? | < 100 mg/dL
113. What is the <b style="color:red;">LDL Target</b> for DM with overt CVD? | < 70 mg/dL
114. What is the <b style="color:red;">Triglyceride Target</b> for DM? | < 150 mg/dL

### IX. COMPARATIVE SUMMARY (TABLES)

115. Compare the <b style="color:red;">Primary Defect</b>: T1DM vs T2DM. | T1: Beta-cell destruction <br>T2: Resistance + exhaustion
116. Compare <b style="color:red;">Body Habitus</b>: T1DM vs T2DM. | T1: Lean <br>T2: Obese/Overweight
117. Compare <b style="color:red;">Insulin Levels</b>: T1DM vs T2DM. | T1: Low/Undetectable <br>T2: High early, Low late
118. Which DM type is strongly associated with <b style="color:red;">HLA (DR3/DR4)</b>? | Type 1 DM
119. Compare <b style="color:red;">Glucose Levels</b>: DKA vs HHS. | DKA: > 250 mg/dL <br>HHS: > 600-1000+ mg/dL
120. Compare <b style="color:red;">Dehydration Degree</b>: DKA vs HHS. | DKA: Moderate <br>HHS: Severe/Profound
121. Compare <b style="color:red;">Ketone Presence</b>: DKA vs HHS. | DKA: Markedly Positive <br>HHS: Absent or trace
122. Compare <b style="color:red;">Serum Bicarbonate</b>: DKA vs HHS. | DKA: Low (<18) <br>HHS: Relatively Normal (>18)
123. What is the <b style="color:red;">Goal</b> of Rapid-acting/Short-acting insulin? | Mealtime coverage/bolus
124. What is the <b style="color:red;">Peak</b> of Short-acting (Regular) insulin? | 2-3 hours
125. What is the <b style="color:red;">Peak</b> of Long-acting insulin? | Peakless
126. Significance: <b style="color:red;">128-Hz Tuning Fork</b>. | Vibration Sensation
127. Significance: <b style="color:red;">Ankle Reflexes</b>. | Nerve Function/Achilles reflex
128. Abnormal Finding: <b style="color:red;">10-g Monofilament</b>. | < 4/10 sites felt
129. Abnormal Finding: <b style="color:red;">Visual Inspection</b> of feet. | Deformities, calluses, ulcers
130. What is the leading world health problem regarding blood sugar? | <b style="color:red;">Diabetes</b>
131. In what trimester does <b style="color:red;">GDM</b> typically develop? | Second or third
132. What is <b style="color:red;">LADA</b> also known as? | Autoimmune diabetes of adults
133. What is the <b style="color:red;">normal PG level</b> 2 hours post-OGTT? | < 140 mg/dL
134. What is the major locus on <b style="color:red;">Chromosome 6</b> for T1DM? | HLA region
135. What does <b style="color:red;">T2DM resistance</b> in adipose tissue lead to? | Increased lipolysis/FFA flux
136. Name rapid-acting <b style="color:red;">insulin types</b>. (3) | Aspart, Lispro, Glulisine
137. Name long-acting <b style="color:red;">insulin types</b>. (3) | Glargine, Detemir, Degludec
138. What describes <b style="color:red;">early morning hyperglycemia</b>? | Dawn Phenomenon
139. What is the <b style="color:red;">preferred agent</b> for initial T2DM? | Metformin
140. Which drug class causes <b style="color:red;">fluid retention</b>? | TZDs (Thiazolidinediones)
141. What is the risk of <b style="color:red;">SGLT2 inhibitors</b> regarding infections? | Genital mycotic infections
142. What pH defines <b style="color:red;">Metabolic Acidosis</b> in DKA? | pH < 7.3
143. What osmolality is seen in <b style="color:red;">HHS</b>? | > 300 mOsm/L
144. What defines <b style="color:red;">blindness</b> risk in diabetics? | Diabetic Retinopathy
145. What lesion is pathognomonic for <b style="color:red;">Nephropathy</b>? | Kimmelstiel-Wilson nodule
146. What distribution defines <b style="color:red;">Symmetric Polyneuropathy</b>? | Stocking-glove
147. What is <b style="color:red;">CAN</b> an independent risk factor for? | CV mortality
148. What should be used for <b style="color:red;">Secondary Prevention</b> in CVD? | Aspirin
149. What is the target <b style="color:red;">Triglyceride</b> level? | < 150 mg/dL
150. What age starts <b style="color:red;">DM screening</b>? | Age 45


# 8
## Summary
text
### I. PITUITARY ANATOMY, DEVELOPMENT, AND PHYSIOLOGY

* The <b style="color:blue;">Anterior Pituitary</b> produces six major hormones: Prolactin (PRL), Growth Hormone (GH), Adrenocorticotropic Hormone (ACTH), Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), and Thyroid-Stimulating Hormone (TSH).
* The <b style="color:blue;">Pituitary Gland</b> is known as the <b style="color:red;">"master gland"</b> because it orchestrates the regulatory functions of many other endocrine glands.
* The <b style="color:blue;">Anterior Pituitary</b> blood supply is derived from the <b style="color:red;">hypothalamic-pituitary portal plexus</b>, allowing releasing/inhibiting hormones to reach it without systemic dilution.
* <b style="color:blue;">Anterior Pituitary Hormones</b> are secreted in a <b style="color:red;">pulsatile manner</b>.
* The <b style="color:blue;">Pituitary Gland</b> weighs approximately 600 mg and sits within the <b style="color:red;">sella turcica</b>.
* <b style="color:blue;">Prop-1</b> is a transcription factor that induces the development of Pit-1-specific lineages and gonadotropes; it is the most common cause of <b style="color:red;">familial Combined Pituitary Hormone Deficiency (CPHD)</b>.
* <b style="color:blue;">Pit-1 (POU1F1)</b> is a transcription factor required for the development of somatotropes (GH), lactotropes (PRL), and thyrotropes (TSH).
* <b style="color:blue;">T-Pit</b> is a transcription factor required for the development of <b style="color:red;">corticotrope cells</b> which express the POMC gene.
* <b style="color:blue;">SF-1 and DAX-1</b> are nuclear receptors that define <b style="color:red;">gonadotrope cell</b> development.

### II. DEVELOPMENTAL AND HYPOTHALAMIC CAUSES OF HYPOPITUITARISM

| Mutation/Syndrome | Hormones Affected | Clinical Key Features |
| :--- | :--- | :--- |
| <b style="color:blue;">Pit-1 Mutation</b> | ↓ GH, ↓ PRL, ↓ TSH | Growth failure, hypoplastic pituitary gland. |
| <b style="color:blue;">PROP1 Mutation</b> | ↓ GH, ↓ PRL, ↓ TSH, ↓ Gonadotropins | Childhood growth retardation, failure to enter puberty, universal TSH/Gn deficiency by adulthood. |
| <b style="color:blue;">TPIT Mutation</b> | ↓ ACTH (Isolated) | Neonatal hypoglycemia, hypocortisolism, recurrent infections. |
| <b style="color:blue;">NR5A1 (SF-1)</b> | ↓ Gonadotropins | Adrenal insufficiency, gonadal failure, disorders of sex development. |
| <b style="color:blue;">Kallmann Syndrome</b> | ↓ GnRH, ↓ LH/FSH | <b style="color:red;">Anosmia/Hyposmia</b>, mirror movements, color blindness, micropenis. |
| <b style="color:blue;">Bardet-Biedl Syndrome</b> | ↓ GnRH | Intellectual disability, <b style="color:red;">hexadactyly</b>, obesity, blindness by age 30. |
| <b style="color:blue;">Prader-Willi Syndrome</b> | ↓ GnRH | <b style="color:red;">Paternal SNRPN deletion</b>, hyperphagia, obesity, muscle hypotonia. |

* <b style="color:blue;">Kallmann Syndrome</b> results from defective hypothalamic GnRH synthesis and is often linked to <b style="color:red;">X-linked KAL gene mutations</b>.
* <b style="color:blue;">Kallmann Syndrome</b> treatment in males involves human chorionic gonadotropin (hCG) or testosterone; in females, cyclic estrogen and progestin are used.
* <b style="color:blue;">Leptin or Leptin Receptor Mutations</b> cause hyperphagia, obesity, and <b style="color:red;">central hypogonadism</b>.

### III. ACQUIRED HYPOPITUITARISM

* <b style="color:blue;">Cranial Irradiation</b> causes hormone loss in a typical pattern: <b style="color:red;">GH deficiency is the most common</b>, followed by gonadotropins, TSH, and ACTH.
* <b style="color:blue;">Lymphocytic Hypophysitis</b> occurs most often in <b style="color:red;">postpartum women</b>, presenting with hyperprolactinemia and a pituitary mass that resembles an adenoma.
* <b style="color:blue;">Lymphocytic Hypophysitis</b> is characterized by an <b style="color:red;">elevated erythrocyte sedimentation rate (ESR)</b> and often resolves with glucocorticoid treatment.
* <b style="color:blue;">Pituitary Apoplexy</b> is an <b style="color:red;">endocrine emergency</b> caused by acute hemorrhagic vascular events, often in a pre-existing adenoma or postpartum (Sheehan's).
* <b style="color:blue;">Pituitary Apoplexy</b> clinical features include severe headache, <b style="color:red;">meningeal irritation</b>, visual changes, and potential cardiovascular collapse.
* <b style="color:blue;">Empty Sella</b> is often an incidental finding where the sella is filled with CSF; <b style="color:red;">pituitary function is usually normal</b>.
* <b style="color:blue;">CTLA-4 Inhibitors (e.g., Ipilimumab)</b> can cause hypophysitis with associated thyroid, adrenal, and gonadal failure in up to 20% of patients.
* <b style="color:blue;">The Order of Hormone Loss</b> in acquired pituitary failure is typically: <b style="color:red;">GH → FSH/LH → TSH → ACTH</b>.

### IV. CLINICAL FEATURES AND EVALUATION OF HORMONE DEFICIENCIES

* <b style="color:blue;">GH Deficiency</b> causes growth disorders in children and <b style="color:red;">increased fat mass/decreased lean muscle</b> in adults.
* <b style="color:blue;">Secondary Hypothyroidism</b> is diagnosed by finding <b style="color:red;">low free T4</b> with a <b style="color:red;">low or inappropriately normal TSH</b>.
* <b style="color:blue;">Secondary Adrenal Insufficiency</b> (ACTH deficiency) features hypocortisolism but <b style="color:red;">preserves mineralocorticoid production</b>; unlike primary failure, there is <b style="color:red;">no hyperpigmentation</b>.
* <b style="color:blue;">Insulin Tolerance Test (ITT)</b> is the gold standard for assessing <b style="color:red;">GH and ACTH reserve</b>; a normal response is a GH increase >5 µg/L when glucose is <40 mg/dL.
* <b style="color:blue;">Adult GH Deficiency (AGHD)</b> is defined by a peak GH response to hypoglycemia of <b style="color:red;">&lt3 µg/L</b>.
* <b style="color:blue;">ITT</b> is <b style="color:red;">contraindicated</b> in patients with epilepsy, ischemic heart disease, or the elderly.
* <b style="color:blue;">Gonadotropin Deficiency</b> is the <b style="color:red;">most common presenting feature</b> of adult hypopituitarism (loss of libido, infertility, amenorrhea).

### V. PITUITARY ADENOMAS AND MASS EFFECTS

* <b style="color:blue;">Pituitary Adenomas</b> are benign neoplasms categorized as microadenomas (<1 cm) or macroadenomas (>1 cm).
* <b style="color:blue;">Optic Chiasm Compression</b> by a suprasellar mass typically leads to <b style="color:red;">bitemporal hemianopia</b> (often superiorly pronounced).
* <b style="color:blue;">Stalk Section Phenomenon</b> occurs when a mass compresses the pituitary stalk, blocking dopamine and causing <b style="color:red;">hyperprolactinemia</b>.
* <b style="color:blue;">Cavernous Sinus Invasion</b> can lead to palsies of <b style="color:red;">CN III, IV, and VI</b>, causing diplopia and ptosis.
* <b style="color:blue;">Prolactinoma</b> is the <b style="color:red;">most common pituitary hormone hypersecretion syndrome</b>.
* <b style="color:blue;">Transsphenoidal Surgery</b> is the desired approach for most pituitary tumors, except rare invasive suprasellar masses.
* <b style="color:blue;">Stereotactic Radiosurgery (Gamma Knife)</b> is used as an adjunct to surgery, especially for residual nonfunctioning tumors.

### VI. SPECIFIC HYPERSECRETORY SYNDROMES

| Syndrome | Primary Diagnostic Test | First-line Treatment |
| :--- | :--- | :--- |
| <b style="color:blue;">Prolactinoma</b> | Basal Fasting PRL (>200 µg/L) | <b style="color:red;">Dopamine Agonists</b> (Cabergoline) |
| <b style="color:blue;">Acromegaly</b> | Serum IGF-1 (Screen) / OGTT (Confirm) | <b style="color:red;">Transsphenoidal Surgery</b> |
| <b style="color:blue;">Cushing’s Disease</b> | 24-hr UFC / Midnight Cortisol / 1-mg Dex | <b style="color:red;">Transsphenoidal Surgery</b> |
| <b style="color:blue;">TSH Adenoma</b> | High T4 + Normal/High TSH | Surgery + Somatostatin Ligands (SRLs) |

* <b style="color:blue;">Prolactinoma</b> treatment: <b style="color:red;">Cabergoline</b> is preferred due to higher efficacy; <b style="color:red;">Bromocriptine</b> is preferred if <b style="color:red;">pregnancy</b> is desired.
* <b style="color:blue;">Acromegaly</b> diagnosis is confirmed by the failure of GH to suppress to <b style="color:red;">&lt0.4 µg/L</b> after a 75g oral glucose load.
* <b style="color:blue;">Acromegaly</b> physical signs include <b style="color:red;">frontal bossing</b>, enlarged hands/feet, macroglossia, and <b style="color:red;">carpal tunnel syndrome</b>.
* <b style="color:blue;">Pegvisomant</b> (GH receptor antagonist) normalizes IGF-1 by blocking peripheral GH binding but <b style="color:red;">does not shrink the tumor</b>.
* <b style="color:blue;">Cushing’s Disease</b> (pituitary ACTH) must be distinguished from ectopic ACTH; <b style="color:red;">Inferior Petrosal Sinus Sampling (IPSS)</b> with a CRH peak ratio ≥3 confirms a pituitary source.
* <b style="color:blue;">Nelson’s Syndrome</b> is the rapid enlargement of a pituitary tumor and <b style="color:red;">hyperpigmentation</b> following bilateral adrenalectomy for Cushing’s.
* <b style="color:blue;">Nonfunctioning Adenomas</b> are usually macroadenomas that present with visual loss and <b style="color:red;">slightly elevated PRL</b> (due to stalk effect).

### VII. EXPERT COMPARISONS AND DIFFERENTIATION

1. <b style="color:blue;">Primary vs. Secondary Hypothyroidism</b>: Primary has <b style="color:red;">High TSH</b>; Secondary (pituitary) has <b style="color:red;">Low/Normal TSH</b> despite low T4.
2. <b style="color:blue;">Primary vs. Secondary Adrenal Insufficiency</b>: Primary (Addison's) features <b style="color:red;">hyperpigmentation</b> and mineralocorticoid loss; Secondary (ACTH def) lacks hyperpigmentation and <b style="color:red;">preserves aldosterone</b>.
3. <b style="color:blue;">Pit-1 vs. PROP-1 Mutation</b>: Pit-1 affects GH, PRL, TSH; PROP-1 affects those <b style="color:red;">PLUS Gonadotropins</b> (LH/FSH).
4. <b style="color:blue;">Microadenoma vs. Macroadenoma</b>: Microadenomas are <b style="color:red;">&lt1 cm</b>; Macroadenomas are <b style="color:red;">>1 cm</b> and cause mass effects.
5. <b style="color:blue;">Cabergoline vs. Bromocriptine</b>: Cabergoline is <b style="color:red;">long-acting</b> (twice weekly) and more effective; Bromocriptine is <b style="color:red;">short-acting</b> and safer for fertility.
6. <b style="color:blue;">Pituitary Cushing’s vs. Ectopic ACTH</b>: Pituitary Cushing's usually shows <b style="color:red;">partial suppression</b> with high-dose dexamethasone; Ectopic ACTH is <b style="color:red;">unresponsive</b> and has higher K+ depletion.
7. <b style="color:blue;">SRLs (Octreotide) vs. Pegvisomant</b>: SRLs <b style="color:red;">inhibit GH secretion</b> and shrink tumors; Pegvisomant <b style="color:red;">blocks the receptor</b> and lowers IGF-1 without shrinking the tumor.
8. <b style="color:blue;">Kallmann Syndrome vs. Bardet-Biedl</b>: Both have GnRH deficiency, but Kallmann features <b style="color:red;">anosmia</b> while Bardet-Biedl features <b style="color:red;">polydactyly/obesity</b>.
9. <b style="color:blue;">Bitemporal vs. Homonymous Hemianopia</b>: Bitemporal denotes <b style="color:red;">chiasm compression</b> (pituitary); Homonymous denotes <b style="color:red;">post-chiasmal compression</b>.
10. <b style="color:blue;">TSH-secreting Adenoma vs. Resistance to Thyroid Hormone</b>: Adenomas usually have a <b style="color:red;">visible pituitary mass</b> and elevated alpha-subunit; Resistance does not.
11. <b style="color:blue;">Insulin Tolerance Test vs. Glucose Suppression Test</b>: ITT tests for <b style="color:red;">Hormone Deficiency</b> (GH/ACTH); Glucose load tests for <b style="color:red;">Hormone Excess</b> (Acromegaly).
12. <b style="color:blue;">Lymphocytic Hypophysitis vs. Pituitary Adenoma</b>: Hypophysitis is usually <b style="color:red;">postpartum</b> with a <b style="color:red;">high ESR</b>; Adenomas are more common and not inflammatory.
13. <b style="color:blue;">Iatrogenic Cushing’s vs. Cushing’s Disease</b>: Iatrogenic is the <b style="color:red;">most common cause</b> of cushingoid features due to exogenous steroids; Disease is due to <b style="color:red;">pituitary ACTH hypersecretion</b>.
14. <b style="color:blue;">Diabetes Insipidus (Central)</b>: Caused by loss of <b style="color:red;">Vasopressin (ADH)</b> from the posterior pituitary, resulting in polyuria/polydipsia.
15. <b style="color:blue;">Acromegaly vs. Gigantism</b>: Acromegaly occurs <b style="color:red;">after epiphyses close</b> (adults); Gigantism occurs <b style="color:red;">before epiphyses close</b> (children).
16. <b style="color:blue;">Pasireotide vs. Octreotide</b>: Pasireotide has higher affinity for <b style="color:red;">SST5</b> (better for Cushing's) and a higher risk of <b style="color:red;">hyperglycemia/diabetes</b>.
17. <b style="color:blue;">Stalk Effect Hyperprolactinemia vs. Prolactinoma</b>: Stalk effect PRL levels are usually <b style="color:red;">&lt100-200 µg/L</b>; Prolactinomas often result in PRL <b style="color:red;">>250 µg/L</b>.
18. <b style="color:blue;">Metyrapone vs. Ketoconazole</b>: Both inhibit cortisol synthesis; Ketoconazole is an <b style="color:red;">antifungal</b>, while Metyrapone is a specific <b style="color:red;">11β-hydroxylase inhibitor</b>.
19. <b style="color:blue;">MEN1 vs. Non-Syndromic Pituitary Tumor</b>: MEN1 involves the <b style="color:red;">3 Ps</b> (Pituitary, Parathyroid, Pancreas) due to menin mutation.
20. <b style="color:blue;">Prader-Willi vs. Obesity-related Hypogonadism</b>: Prader-Willi is a <b style="color:red;">genetic syndrome</b> with hypotonia and "paternal deletion"; simple obesity isn't.


## QA
text
### I. PITUITARY ANATOMY, DEVELOPMENT, AND PHYSIOLOGY

1. Which structure produces the hormones PRL, GH, ACTH, LH, FSH, and TSH? | <b style="color:blue;">Anterior Pituitary</b>
2. List the six major hormones produced by the <b style="color:blue;">Anterior Pituitary</b>. | PRL, GH, ACTH, <br>LH, FSH, TSH
3. Why is the <b style="color:blue;">Pituitary Gland</b> referred to as the <b style="color:red;">"master gland"</b>? | Orchestrates other endocrine glands
4. From where is the blood supply of the <b style="color:blue;">Anterior Pituitary</b> derived? | <b style="color:red;">Hypothalamic-pituitary portal plexus</b>
5. What is the functional advantage of the <b style="color:red;">hypothalamic-pituitary portal plexus</b>? | Prevents systemic hormone dilution
6. Characterize the secretion pattern of <b style="color:blue;">Anterior Pituitary Hormones</b>. | <b style="color:red;">Pulsatile manner</b>
7. What is the approximate weight of the <b style="color:blue;">Pituitary Gland</b>? | 600 mg
8. Name the bony structure where the <b style="color:blue;">Pituitary Gland</b> is located. | <b style="color:red;">Sella turcica</b>
9. Which transcription factor induces Pit-1-specific lineages and gonadotropes? | <b style="color:blue;">Prop-1</b>
10. What is the most common cause of <b style="color:red;">familial Combined Pituitary Hormone Deficiency (CPHD)</b>? | <b style="color:blue;">Prop-1 mutation</b>
11. Name the transcription factor required for GH, PRL, and TSH development. | <b style="color:blue;">Pit-1 (POU1F1)</b>
12. Development of which cells depends on the transcription factor <b style="color:blue;">Pit-1</b>? (3) | Somatotropes, lactotropes, and thyrotropes
13. Which transcription factor is required for <b style="color:red;">corticotrope cell</b> development? | <b style="color:blue;">T-Pit</b>
14. Which gene is expressed by <b style="color:red;">corticotrope cells</b> under the influence of T-Pit? | POMC gene
15. Which nuclear receptors define the development of <b style="color:red;">gonadotrope cells</b>? (2) | <b style="color:blue;">SF-1 and DAX-1</b>

### II. DEVELOPMENTAL AND HYPOTHALAMIC CAUSES OF HYPOPITUITARISM

16. Which hormones are deficient in a <b style="color:blue;">Pit-1 Mutation</b>? (3) | GH, PRL, and TSH
17. Identify the clinical features of <b style="color:blue;">Pit-1 Mutation</b>. (2) | Growth failure and <br>hypoplastic pituitary gland
18. Which hormones are deficient in <b style="color:blue;">PROP1 Mutation</b>? (4) | GH, PRL, TSH, <br>and Gonadotropins
19. What is a key developmental feature of <b style="color:blue;">PROP1 Mutation</b> by adulthood? | Universal TSH/Gn deficiency
20. Which hormone is isolated in its deficiency during a <b style="color:blue;">TPIT Mutation</b>? | <b style="color:red;">ACTH</b>
21. List clinical features of <b style="color:blue;">TPIT Mutation</b>. (3) | Neonatal hypoglycemia, <br>hypocortisolism, and infections
22. Which mutation causes Adrenal insufficiency and disorders of sex development? | <b style="color:blue;">NR5A1 (SF-1)</b>
23. What hormones are deficient in <b style="color:blue;">NR5A1 (SF-1) Mutation</b>? | Gonadotropins
24. <b style="color:blue;">Kallmann Syndrome</b> results from a deficiency in which hypothalamic hormone? | <b style="color:red;">GnRH</b>
25. List the key clinical features of <b style="color:blue;">Kallmann Syndrome</b> (4). | <b style="color:red;">Anosmia</b>, mirror movements, <br>color blindness, micropenis
26. Which hormone deficiency is central to <b style="color:blue;">Bardet-Biedl Syndrome</b>? | GnRH
27. Identify the hallmark physical finding in <b style="color:blue;">Bardet-Biedl Syndrome</b>. | <b style="color:red;">Hexadactyly</b> (six fingers)
28. List secondary clinical features of <b style="color:blue;">Bardet-Biedl Syndrome</b> (3). | Intellectual disability, obesity, <br>and blindness
29. Describe the genetic cause of <b style="color:blue;">Prader-Willi Syndrome</b>. | <b style="color:red;">Paternal SNRPN deletion</b>
30. What are the clinical manifestations of <b style="color:blue;">Prader-Willi Syndrome</b>? (3) | Hyperphagia, obesity, and <br>muscle hypotonia
31. What mutation is most commonly linked to <b style="color:blue;">Kallmann Syndrome</b>? | <b style="color:red;">X-linked KAL gene</b>
32. How is <b style="color:blue;">Kallmann Syndrome</b> treated in males? (2) | hCG or testosterone
33. How is <b style="color:blue;">Kallmann Syndrome</b> treated in females? | Cyclic estrogen and progestin
34. What clinical triad results from <b style="color:blue;">Leptin Receptor Mutations</b>? | Hyperphagia, obesity, and <br>central hypogonadism

### III. ACQUIRED HYPOPITUITARISM

35. What is the most common hormone lost due to <b style="color:blue;">Cranial Irradiation</b>? | <b style="color:red;">GH deficiency</b>
36. Describe the typical pattern of hormone loss after <b style="color:blue;">Cranial Irradiation</b>. | GH → Gn → TSH → ACTH
37. In which patient population does <b style="color:blue;">Lymphocytic Hypophysitis</b> most often occur? | <b style="color:red;">Postpartum women</b>
38. How does <b style="color:blue;">Lymphocytic Hypophysitis</b> appear on imaging? | Pituitary mass resembling adenoma
39. Which inflammatory marker is elevated in <b style="color:blue;">Lymphocytic Hypophysitis</b>? | <b style="color:red;">ESR</b>
40. What is the first-line medical treatment for <b style="color:blue;">Lymphocytic Hypophysitis</b>? | Glucocorticoids
41. What defines <b style="color:blue;">Pituitary Apoplexy</b>? | Acute hemorrhagic vascular event
42. In what setting does <b style="color:blue;">Pituitary Apoplexy</b> usually occur? (2) | Pre-existing adenoma or <br>postpartum (Sheehan's)
43. Why is <b style="color:blue;">Pituitary Apoplexy</b> considered an <b style="color:red;">endocrine emergency</b>? | Risk of cardiovascular collapse
44. List the clinical features of <b style="color:blue;">Pituitary Apoplexy</b>. (4) | Severe headache, <br>meningeal irritation, <br>visual changes, collapse
45. Define <b style="color:blue;">Empty Sella</b>. | Sella filled with CSF
46. What is the baseline pituitary function in most cases of <b style="color:blue;">Empty Sella</b>? | <b style="color:red;">Usually normal</b>
47. Which drug class includes <b style="color:blue;">Ipilimumab</b> and causes hypophysitis? | <b style="color:red;">CTLA-4 Inhibitors</b>
48. What percentage of patients on <b style="color:blue;">CTLA-4 Inhibitors</b> develop hypophysitis? | Up to 20%
49. Provide the specific <b style="color:blue;">Order of Hormone Loss</b> in acquired pituitary failure. | GH → FSH/LH → TSH → ACTH

### IV. CLINICAL FEATURES AND EVALUATION OF HORMONE DEFICIENCIES

50. What are the clinical signs of <b style="color:blue;">GH Deficiency</b> in adults? (2) | Increased fat mass and <br>decreased lean muscle
51. How is <b style="color:blue;">Secondary Hypothyroidism</b> diagnosed via labs? | <b style="color:red;">Low free T4</b> with <br>low/normal TSH
52. Which hormone production is preserved in <b style="color:blue;">Secondary Adrenal Insufficiency</b>? | <b style="color:red;">Mineralocorticoids</b> (Aldosterone)
53. What physical finding distinguishes primary from <b style="color:blue;">Secondary Adrenal Insufficiency</b>? | <b style="color:red;">No hyperpigmentation</b> in secondary
54. Name the gold standard test for assessing <b style="color:blue;">GH and ACTH reserve</b>. | <b style="color:red;">Insulin Tolerance Test (ITT)</b>
55. What is a normal GH response during an <b style="color:blue;">ITT</b> when glucose is <40 mg/dL? | GH increase >5 µg/L
56. What peak GH response defines <b style="color:blue;">Adult GH Deficiency (AGHD)</b> during ITT? | <b style="color:red;"><3 µg/L</b>
57. List three contraindications for the <b style="color:blue;">Insulin Tolerance Test</b>. | Epilepsy, heart disease, <br>and the elderly
58. What is the <b style="color:red;">most common presenting feature</b> of adult hypopituitarism? | <b style="color:blue;">Gonadotropin Deficiency</b>
59. List symptoms associated with <b style="color:blue;">Gonadotropin Deficiency</b> in adults. (3) | Loss of libido, infertility, <br>and amenorrhea

### V. PITUITARY ADENOMAS AND MASS EFFECTS

60. Distinguish <b style="color:blue;">Microadenomas</b> from Macroadenomas by size. | Microadenomas are <1 cm
61. What size defines a <b style="color:blue;">Pituitary Macroadenoma</b>? | <b style="color:red;">>1 cm</b>
62. Which visual defect is classic for <b style="color:blue;">Optic Chiasm Compression</b>? | <b style="color:red;">Bitemporal hemianopia</b>
63. Describe the <b style="color:blue;">Stalk Section Phenomenon</b>. | Mass blocks dopamine flow
64. What is the hormonal result of the <b style="color:blue;">Stalk Section Phenomenon</b>? | Hyperprolactinemia
65. Which cranial nerves are affected by <b style="color:blue;">Cavernous Sinus Invasion</b>? | III, IV, and VI
66. What are the clinical signs of <b style="color:blue;">Cavernous Sinus Invasion</b>? (2) | Diplopia and ptosis
67. What is the <b style="color:red;">most common</b> pituitary hormone hypersecretion syndrome? | <b style="color:blue;">Prolactinoma</b>
68. What is the surgical approach of choice for most pituitary tumors? | <b style="color:red;">Transsphenoidal Surgery</b>
69. When is <b style="color:blue;">Stereotactic Radiosurgery (Gamma Knife)</b> typically utilized? | Adjunct for residual <br>nonfunctioning tumors

### VI. SPECIFIC HYPERSECRETORY SYNDROMES

70. What basal fasting PRL level suggests <b style="color:blue;">Prolactinoma</b>? | >200 µg/L
71. Name the first-line treatment for <b style="color:blue;">Prolactinoma</b>. | <b style="color:red;">Dopamine Agonists</b> (Cabergoline)
72. List the screening and confirmatory tests for <b style="color:blue;">Acromegaly</b>. | Screen: Serum IGF-1 <br>Confirm: OGTT
73. What is the first-line treatment for <b style="color:blue;">Acromegaly</b>? | <b style="color:red;">Transsphenoidal Surgery</b>
74. List three primary diagnostic tests for <b style="color:blue;">Cushing’s Disease</b>. | 24-hr UFC, Midnight Cortisol, <br>1-mg Dexamethasone suppression
75. What is the surgical first-line treatment for <b style="color:blue;">Cushing’s Disease</b>? | <b style="color:red;">Transsphenoidal Surgery</b>
76. Describe the lab profile of a <b style="color:blue;">TSH Adenoma</b>. | High T4 + Normal/High TSH
77. What is the first-line medical management for <b style="color:blue;">TSH Adenoma</b>? | Surgery + Somatostatin Ligands
78. Why is <b style="color:blue;">Cabergoline</b> preferred over Bromocriptine for Prolactinomas? | Higher efficacy
79. When is <b style="color:blue;">Bromocriptine</b> the preferred treatment for Prolactinoma? | If <b style="color:red;">pregnancy</b> is desired
80. What GH value post-75g oral glucose load confirms <b style="color:blue;">Acromegaly</b>? | GH failure to suppress <0.4 µg/L
81. List physical signs of <b style="color:blue;">Acromegaly</b>. (4) | Frontal bossing, enlarged hands, <br>macroglossia, Carpal tunnel
82. What is the mechanism of action of <b style="color:blue;">Pegvisomant</b>? | GH receptor antagonist
83. Does <b style="color:blue;">Pegvisomant</b> reduce the size of the pituitary tumor? | <b style="color:red;">No</b>
84. Which procedure distinguishes <b style="color:blue;">Cushing’s Disease</b> from ectopic ACTH? | <b style="color:red;">IPSS</b> (Inferior Petrosal Sinus Sampling)
85. What IPSS CRH peak ratio confirms a pituitary source of <b style="color:red;">ACTH</b>? | ≥3
86. Define <b style="color:blue;">Nelson’s Syndrome</b>. | Rapid tumor enlargement <br>after bilateral adrenalectomy
87. What physical finding is characteristic of <b style="color:blue;">Nelson’s Syndrome</b>? | <b style="color:red;">Hyperpigmentation</b>
88. How do <b style="color:blue;">Nonfunctioning Adenomas</b> typically present? (2) | Visual loss and <br>slightly elevated PRL

### VII. EXPERT COMPARISONS AND DIFFERENTIATION

89. Compare TSH levels in <b style="color:blue;">Primary vs. Secondary Hypothyroidism</b>. | Primary: High TSH <br>Secondary: Low/Normal TSH
90. Compare pigmentation in <b style="color:blue;">Primary vs. Secondary Adrenal Insufficiency</b>. | Primary: Hyperpigmentation <br>Secondary: Absent
91. Compare mineralocorticoids in <b style="color:blue;">Primary vs. Secondary Adrenal Insufficiency</b>. | Primary: Lost <br>Secondary: Preserved
92. What extra hormones are affected in <b style="color:blue;">PROP-1</b> vs. Pit-1 mutations? | <b style="color:red;">Gonadotropins</b> (LH/FSH)
93. Compare the size of <b style="color:blue;">Microadenomas vs. Macroadenomas</b>. | Micro: <1 cm <br>Macro: >1 cm
94. Compare the dosing frequency of <b style="color:blue;">Cabergoline vs. Bromocriptine</b>. | Cabergoline: Twice weekly <br>Bromocriptine: Daily
95. Compare high-dose dexamethasone response in <b style="color:blue;">Pituitary Cushing’s vs. Ectopic ACTH</b>. | Pituitary: Partial suppression <br>Ectopic: Unresponsive
96. Compare <b style="color:blue;">SRLs (Octreotide) vs. Pegvisomant</b> regarding GH secretion. | SRLs: Inhibit secretion <br>Pegvisomant: Block receptors
97. Compare <b style="color:blue;">SRLs vs. Pegvisomant</b> regarding tumor shrinkage. | SRLs: Shrink tumor <br>Pegvisomant: No effect
98. Compare <b style="color:blue;">Kallmann vs. Bardet-Biedl</b> regarding sensory findings. | Kallmann: <b style="color:red;">Anosmia</b> <br>Bardet-Biedl: Blindness
99. Distinguish <b style="color:blue;">Kallmann vs. Bardet-Biedl</b> by physical extremities. | Bardet-Biedl has <b style="color:red;">polydactyly</b>
100. Compare the site of compression in <b style="color:blue;">Bitemporal vs. Homonymous Hemianopia</b>. | Bitemporal: Chiasm <br>Homonymous: Post-chiasmal
101. Compare the appearance of <b style="color:blue;">TSH Adenoma vs. Thyroid Hormone Resistance</b>. | Adenoma: Pituitary mass <br>Resistance: No mass
102. Compare the purpose of <b style="color:blue;">ITT vs. Glucose Suppression Test</b>. | ITT: Deficiency (GH/ACTH) <br>Glucose: Excess (Acromegaly)
103. Compare <b style="color:blue;">Lymphocytic Hypophysitis vs. Pituitary Adenoma</b> by ESR. | Hypophysitis: High ESR <br>Adenoma: Normal ESR
104. Distinguish <b style="color:blue;">Iatrogenic Cushing’s</b> from Cushing’s Disease. | Iatrogenic: Exogenous steroids <br>Disease: Pituitary ACTH
105. What is the <b style="color:red;">most common cause</b> of Cushingoid features? | <b style="color:blue;">Iatrogenic Cushing's</b>
106. What hormone is lost in <b style="color:blue;">Central Diabetes Insipidus</b>? | <b style="color:red;">Vasopressin (ADH)</b>
107. Distinguish <b style="color:blue;">Acromegaly vs. Gigantism</b> by timing of epiphyses closure. | Acromegaly: After closure <br>Gigantism: Before closure
108. Compare the receptor affinity of <b style="color:blue;">Pasireotide vs. Octreotide</b>. | Pasireotide: Higher SST5 affinity
109. What is a significant side effect of <b style="color:blue;">Pasireotide</b>? | <b style="color:red;">Hyperglycemia</b>
110. Compare <b style="color:blue;">Stalk Effect PRL vs. Prolactinoma</b> PRL levels. | Stalk Effect: <200 µg/L <br>Prolactinoma: >250 µg/L
111. Distinguish <b style="color:blue;">Ketoconazole vs. Metyrapone</b> mechanisms. | Ketoconazole: Antifungal inhibitor <br>Metyrapone: 11β-hydroxylase inhibitor
112. List the components of the <b style="color:blue;">"3 Ps"</b> in MEN1. | Pituitary, Parathyroid, Pancreas
113. Distinguish <b style="color:blue;">Prader-Willi vs. Obesity-related Hypogonadism</b> genetically. | Prader-Willi has <b style="color:red;">paternal SNRPN deletion</b>
114. What are the neonatal features of <b style="color:blue;">Isolated ACTH deficiency (TPIT)</b>? | Hypoglycemia and hypocortisolism
115. Which nuclear receptor is associated with adrenal insufficiency and sex development disorders? | <b style="color:blue;">SF-1 (NR5A1)</b>
116. What visual finding is associated with <b style="color:blue;">Bardet-Biedl Syndrome</b>? | Blindness by age 30
117. What is the most common cause of <b style="color:red;">hyperprolactinemia</b> in someone with a nonfunctioning macroadenoma? | <b style="color:blue;">Stalk effect</b>
118. Which drug is preferred for Cushing's due to high SST5 affinity? | <b style="color:red;">Pasireotide</b>
119. What gene mutation is central to <b style="color:blue;">MEN1</b>? | Menin mutation
120. Which hormone deficiency is tested when <b style="color:blue;">ITT</b> results in glucose <40 mg/dL? | <b style="color:red;">GH and ACTH</b>



# 9
## Summary
text
### I. POSTERIOR PITUITARY (NEUROHYPOPHYSIS) OVERVIEW

| Feature | Details |
| :--- | :--- |
| <b style="color:blue;">Anatomy</b> | Composed of large neuronal axons originating in the supraoptic and paraventricular nuclei of the hypothalamus. |
| <b style="color:blue;">Hormone Storage</b> | Axons terminate as bulbous enlargements on a capillary plexus; hormones are stored here and released into the systemic circulation. |
| <b style="color:red;">Arginine Vasopressin (AVP)</b> | Primary hormone that acts on renal tubules to reduce water loss by concentrating urine. |
| <b style="color:red;">Oxytocin</b> | Hormone that stimulates postpartum milk letdown in response to suckling and facilitates uterine contractions during labor. |

* The <b style="color:blue;">Posterior Pituitary blood supply</b> terminates in a capillary plexus that drains eventually into the superior vena cava.
* <b style="color:blue;">Arginine Vasopressin (AVP) deficiency</b> or action failure results in <b style="color:red;">Diabetes Insipidus (DI)</b>, characterized by large volumes of dilute urine.
* <b style="color:blue;">Excessive AVP production</b> results in <b style="color:red;">Syndrome of Inappropriate Antidiuretic Hormone (SIADH)</b>, leading to hyponatremia and impaired water excretion.

### II. ARGININE VASOPRESSIN (AVP) PHYSIOLOGY AND ACTION

| Aspect | Physiology and Mechanism |
| :--- | :--- |
| <b style="color:blue;">Regulation</b> | Mediated by <b style="color:red;">osmoreceptors</b> in the anteromedial hypothalamus, sensitive to plasma sodium concentration. |
| <b style="color:blue;">Secretion Threshold</b> | AVP release begins at a plasma osmolarity of approximately <b style="color:red;">275 mosmol/L</b> (Na ~135 meq/L). |
| <b style="color:blue;">Stimuli</b> | Stimulated by hyperosmolarity, volume loss (>10-20%), nausea, hypoglycemia, and glucocorticoid deficiency. |
| <b style="color:blue;">Renal Action</b> | Binds to <b style="color:red;">V2 receptors</b> on the basolateral surface of principal cells in the distal tubule and medullary collecting ducts. |
| <b style="color:blue;">Aquaporin-2</b> | V2 receptor activation triggers the insertion of <b style="color:red;">Aquaporin-2 water channels</b> into the apical membrane for water reabsorption. |
| <b style="color:blue;">Metabolism</b> | AVP has a half-life of <b style="color:red;">10–30 minutes</b> and is cleared by the liver and kidneys. |

* The <b style="color:red;">most potent stimulus</b> for AVP secretion is <b style="color:red;">nausea</b>, which can increase plasma AVP levels 50 to 100-fold.
* During <b style="color:blue;">pregnancy</b>, the metabolic clearance of AVP increases 3-4 fold due to placental production of <b style="color:red;">N-terminal peptidase</b>.
* In the <b style="color:blue;">absence of AVP</b>, principal cells remain impermeable to water, resulting in a maximum urine output of ~0.2 mL/kg/min and a specific gravity of ~1.000.
* The <b style="color:blue;">thirst osmostat</b> is generally set about 3% higher than the AVP osmostat to ensure adequate fluid intake before dehydration becomes severe.

### III. DIABETES INSIPIDUS (DI): ETIOLOGY AND CLINICAL FEATURES

| Type of DI | Primary Cause / Mechanism |
| :--- | :--- |
| <b style="color:red;">Pituitary (Central) DI</b> | Most common type; primary deficiency of AVP secretion, often due to <b style="color:blue;">AVP-NPII gene mutations</b> or head trauma. |
| <b style="color:red;">Nephrogenic DI</b> | Renal insensitivity to AVP. Most common genetic form is <b style="color:blue;">X-linked V2 receptor mutation</b>; can also be caused by <b style="color:blue;">Lithium</b> or <b style="color:blue;">Hypokalemia</b>. |
| <b style="color:red;">Primary Polydipsia</b> | Suppression of AVP by excessive fluid intake; includes <b style="color:blue;">Dipsogenic</b> (inappropriate thirst), <b style="color:blue;">Psychogenic</b>, and <b style="color:blue;">Iatrogenic</b> forms. |
| <b style="color:red;">Gestational DI</b> | Transient deficiency of AVP caused by rapid degradation by <b style="color:blue;">placental N-terminal aminopeptidase</b>. |

* <b style="color:blue;">Diabetes Insipidus</b> is clinically defined by a 24-hour urine volume exceeding <b style="color:red;">40 mL/kg body weight</b> and a urine osmolarity <b style="color:red;"><280 mosm/L</b>.
* The <b style="color:blue;">hallmark symptoms of DI</b> are polyuria (nocturia, enuresis) and <b style="color:red;">polydipsia</b> (excessive thirst) due to rising plasma osmolarity.
* <b style="color:blue;">Dipsogenic DI</b> is a form of primary polydipsia where the thirst threshold is abnormally low, often following head trauma or neurosarcoidosis.
* In <b style="color:blue;">Nephrogenic DI</b>, urine remains dilute despite high levels of circulating AVP because the kidneys cannot respond to the hormone.

### IV. DIAGNOSTIC EVALUATION OF DIABETES INSIPIDUS

| Diagnostic Step | Purpose and Finding |
| :--- | :--- |
| <b style="color:blue;">Exclusion of Glucosuria</b> | Mandatory first step to rule out <b style="color:red;">Diabetes Mellitus</b> as the cause of polyuria. |
| <b style="color:blue;">Basal Na/Osmolarity</b> | High plasma Na/Osm rules out <b style="color:red;">Primary Polydipsia</b>; further fluid deprivation is hazardous if hypernatremic. |
| <b style="color:blue;">Fluid Deprivation Test</b> | Traditional method; failure to concentrate urine after 4-6 hours of restriction suggests DI. |
| <b style="color:blue;">Desmopressin Challenge</b> | Distinguishes Pituitary (concentrates urine) from Nephrogenic DI (no response). |
| <b style="color:blue;">Plasma AVP Measurement</b> | Gold standard for <b style="color:red;">partial defects</b>; confirms AVP deficiency vs. renal resistance. |
| <b style="color:blue;">Brain MRI</b> | Looking for the <b style="color:red;">posterior pituitary "bright spot"</b> (stored AVP); usually absent in Pituitary DI. |

* A <b style="color:blue;">Desmopressin therapeutic trial</b> in <b style="color:red;">Primary Polydipsia</b> eliminates polyuria but not the urge to drink, leading to severe hyponatremia within 8-24 hours.
* The <b style="color:blue;">Posterior Pituitary "bright spot"</b> on T1-weighted MRI reflects stored AVP and is almost always present in <b style="color:red;">Primary Polydipsia</b> but absent in <b style="color:red;">Pituitary DI</b>.
* <b style="color:blue;">Hypertonic saline infusion (3% NaCl)</b> may be used to raise plasma osmolarity to ensure accurate interpretation of AVP levels when fluid deprivation alone is insufficient.
* <b style="color:blue;">Copeptin</b> is a peptide co-secreted with AVP; while stable, its baseline levels are not currently diagnostic for DI types.

### V. MANAGEMENT OF DIABETES INSIPIDUS

| Type of DI | Primary Treatment Strategy |
| :--- | :--- |
| <b style="color:blue;">Pituitary (Central) DI</b> | First-line: <b style="color:red;">Desmopressin (DDAVP)</b>. Synthetic V2-selective analogue with a long duration of action. |
| <b style="color:blue;">Nephrogenic DI</b> | Low-sodium diet, Thiazide diuretics, Amiloride, and <b style="color:red;">Indomethacin</b> (prostaglandin inhibitor). |
| <b style="color:blue;">Primary Polydipsia</b> | Behavioral modification; <b style="color:red;">DDAVP is contraindicated</b> due to the high risk of water intoxication/hyponatremia. |

* <b style="color:blue;">Desmopressin (DDAVP)</b> is preferred over native AVP for Pituitary DI because it has <b style="color:red;">3–4× longer duration</b> and lacks the pressor (V1) effects.
* The goal of <b style="color:blue;">DDAVP therapy</b> is a target urine volume of <b style="color:red;">15–30 mL/kg/day</b> and urine osmolarity of 400–800 mOsm/L.
* In <b style="color:blue;">Nephrogenic DI</b>, Thiazides work paradoxically by inducing mild volume depletion, which increases proximal tubular reabsorption of water.
* For <b style="color:blue;">Pituitary DI</b>, oral DDAVP doses (100–400 µg) are significantly higher than IV/SC doses (1–2 µg) due to low bioavailability.

### VI. HYPODIPSIC HYPERNATREMIA

| Feature | Details |
| :--- | :--- |
| <b style="color:blue;">Definition</b> | Chronic or recurrent <b style="color:red;">hypertonic dehydration</b> due to a lack of thirst (hypodipsia) and failure to drink water. |
| <b style="color:blue;">Etiology</b> | Destruction of <b style="color:red;">osmoreceptors</b> in the anterior hypothalamus (e.g., ACOM artery surgery, tumors, sarcoidosis). |
| <b style="color:blue;">Clinical Signs</b> | Tachycardia, postural hypotension, azotemia, and <b style="color:red;">secondary hyperaldosteronism</b> (leading to hypokalemia). |
| <b style="color:blue;">Diagnosis</b> | Documented hypernatremia in a conscious patient who <b style="color:red;">denies thirst</b> and fails to drink spontaneously. |

* Treatment of <b style="color:blue;">Hypodipsic Hypernatremia</b> involves calculating the <b style="color:red;">free water deficit (ΔFW)</b> using the formula: ΔFW = 0.5 \times BW \times ([SNa - 140]/140).
* In <b style="color:blue;">Hypodipsic Hypernatremia</b>, AVP secretion responds normally to non-osmotic stimuli (nausea, hypotension), confirming the neurohypophysis is intact but the osmoreceptors are not.
* When treating <b style="color:blue;">Hypodipsic Hypernatremia</b> with concurrent Pituitary DI, <b style="color:red;">DDAVP therapy</b> may be required to complete rehydration.

### VII. INAPPROPRIATE ANTIDIURESIS (SIADH)

| Type | Etiology and Characteristics |
| :--- | :--- |
| <b style="color:blue;">SIADH</b> | Hypo-osmolemic hyponatremia due to <b style="color:red;">inappropriate AVP secretion</b> in the absence of non-osmotic stimuli. |
| <b style="color:blue;">Nephrogenic SIAD (NSIAD)</b> | Failure to dilute urine due to <b style="color:red;">activating mutations</b> of the V2 receptor; AVP levels are often undetectable. |
| <b style="color:blue;">Type I (Hypervolemic)</b> | Associated with <b style="color:red;">CHF, cirrhosis, or nephrosis</b>; characterized by generalized edema. |
| <b style="color:blue;">Type II (Hypovolemic)</b> | Associated with sodium/water loss (vomiting, diarrhea, <b style="color:red;">Addison’s</b>); hypotension and high PRA are present. |
| <b style="color:blue;">Type III (Euvolemic)</b> | Classic <b style="color:red;">SIADH/NSIAD</b> or cortisol/thyroxine deficiency; no edema, low PRA, and slightly elevated urine Na. |

* <b style="color:blue;">Pathophysiology of SIADH</b> involves a slight expansion of total body water which <b style="color:red;">suppresses Renin and Aldosterone</b>, leading to modest natriuresis but no clinical edema.
* Symptoms of <b style="color:blue;">SIADH</b> result from increased <b style="color:red;">intracranial pressure</b> due to cellular brain swelling as water moves into cells.
* <b style="color:blue;">V2-receptor antagonists (Vaptans)</b> like Tolvaptan (oral) or Conivaptan (IV) are used to treat severe/symptomatic euvolemic hyponatremia.
* <b style="color:blue;">Chronic SIADH</b> symptoms may subside after several days because the brain inactivates intracellular solutes to reduce cellular volume.

### VIII. MANAGEMENT AND COMPLICATIONS OF HYPONATREMIA

| Scenario | Treatment and Precautions |
| :--- | :--- |
| <b style="color:blue;">Hypervolemic Hyponatremia</b> | Restrict fluids; <b style="color:red;">Hypertonic saline is absolutely contraindicated</b> as it worsens edema and heart failure. |
| <b style="color:blue;">Hypovolemic Hyponatremia</b> | Replace deficit with <b style="color:red;">Isotonic (0.9%) or Hypertonic saline</b>; fluid restriction is contraindicated. |
| <b style="color:blue;">Severe Euvolemic SIADH</b> | <b style="color:red;">3% Hypertonic Saline</b> at 0.05 mL/kg/min; raises Na by 1–2 meq/L per hour. |
| <b style="color:blue;">Target Rate of Rise</b> | Keep rate of Na rise at <b style="color:red;">~1% per hour</b>; stop treatment once Na reaches ~130 meq/L. |

* Rapid correction of hyponatremia can lead to <b style="color:red;">Central Pontine Myelinolysis (Osmotic Demyelination)</b>, causing quadriparesis and ataxia.
* In <b style="color:blue;">NSIAD</b> (activating V2 receptor mutation), <b style="color:red;">Vaptans may fail</b>; osmotic diuretics like <b style="color:red;">Urea</b> may be used for long-term prevention.
* <b style="color:blue;">Tolvaptan</b> treatment requires close monitoring of fluid intake to avoid over-correction and resultant <b style="color:red;">hypernatremia</b>.

### IX. COMPARATIVE DIFFERENTIATION OF DISORDERS

| Comparison | Key Differentiating Feature |
| :--- | :--- |
| <b style="color:blue;">Pituitary DI vs. Nephrogenic DI</b> | <b style="color:red;">Desmopressin response</b>: Pituitary DI concentrates urine (>50% increase in Osm); Nephrogenic DI shows no/minimal response. |
| <b style="color:blue;">DI vs. Primary Polydipsia (MRI)</b> | <b style="color:red;">Posterior Pituitary Bright Spot</b>: Present in Primary Polydipsia; Absent/Small in Pituitary DI. |
| <b style="color:blue;">DI vs. Primary Polydipsia (Desmopressin)</b> | <b style="color:red;">Natremia outcome</b>: DDAVP stabilizes Pituitary DI; DDAVP causes rapid <b style="color:red;">hyponatremia</b> in Primary Polydipsia. |
| <b style="color:blue;">SIADH vs. Hypervolemic Hyponatremia</b> | <b style="color:red;">Edema</b>: Present in CHF/Cirrhosis (Hypervolemic); Absent in SIADH (Euvolemic). |
| <b style="color:blue;">Primary vs. Secondary Adrenal Insufficiency</b> | <b style="color:red;">Aldosterone/Potassium</b>: Primary (Addison's) loses aldosterone (high K); Secondary (pituitary) preserves aldosterone (normal K). |
| <b style="color:blue;">Hypodipsic Hypernatremia vs. Excess Na Intake</b> | <b style="color:red;">Volume Status</b>: Hypodipsia presents with <b style="color:red;">hypovolemia</b>; excess salt intake presents with <b style="color:red;">hypervolemia</b>. |
| <b style="color:blue;">Central DI vs. Gestational DI</b> | <b style="color:red;">Timing</b>: Gestational DI occurs during pregnancy due to placental enzyme and remits postpartum; Central DI is usually permanent. |
| <b style="color:blue;">SIADH vs. NSIAD</b> | <b style="color:red;">AVP Level</b>: SIADH has <b style="color:red;">elevated AVP</b>; NSIAD has <b style="color:red;">undetectable AVP</b> (due to a mutated receptor constantly "on"). |
| <b style="color:blue;">AVP vs. Thirst Osmostat</b> | <b style="color:red;">Sensitivity</b>: Thirst osmostat is set ~3% <b style="color:red;">higher</b> than AVP; AVP responds first to preserve water before thirst drives intake. |
| <b style="color:blue;">V1 vs. V2 Receptors</b> | <b style="color:red;">Action</b>: V1 causes vasoconstriction (pressor); V2 causes water reabsorption in the kidney (antidiuretic). DDAVP is V2-selective. |


## QA
1. Anatomy: Which structure is the <b style="color:blue;">Posterior Pituitary</b> composed of? | Large neuronal axons. Originating in the hypothalamus.
2. Anatomy: In which hypothalamic nuclei do the axons of the <b style="color:blue;">Neurohypophysis</b> originate? (2) | Supraoptic and paraventricular nuclei.
3. Hormone Storage: Where do <b style="color:blue;">Posterior Pituitary</b> axons terminate? | Capillary plexus. Specifically on bulbous enlargements.
4. Hormone Storage: Where are <b style="color:blue;">Posterior Pituitary</b> hormones stored before release? | Bulbous enlargements. Located on the capillary plexus.
5. Arginine Vasopressin (AVP): What is the primary renal function of <b style="color:red;">AVP</b>? | Reduces water loss. Consisted of concentrating the urine.
6. Oxytocin: What is the role of <b style="color:red;">Oxytocin</b> in the postpartum period? | Milk letdown. In response to suckling.
7. Oxytocin: What is the role of <b style="color:red;">Oxytocin</b> during labor? | Facilitates uterine contractions.
8. Anatomy: Where does the <b style="color:blue;">Posterior Pituitary blood supply</b> eventually drain? | Superior vena cava. Originating from a capillary plexus.
9. Diabetes Insipidus (DI): What cause leads to <b style="color:red;">Diabetes Insipidus</b>? | AVP deficiency or action failure.
10. Diabetes Insipidus (DI): What are the urine characteristics of <b style="color:red;">DI</b>? | Large volumes of dilute urine.
11. SIADH: What results from <b style="color:red;">excessive AVP production</b>? | SIADH. Leads to hyponatremia and impaired water excretion.
12. AVP Regulation: What hypothalamic structures mediate <b style="color:red;">Arginine Vasopressin (AVP)</b> regulation? | Osmoreceptors. Located in the anteromedial hypothalamus.
13. AVP Regulation: To what specific concentration are hypothalamic <b style="color:red;">osmoreceptors</b> sensitive? | Plasma sodium concentration.
14. Secretion Threshold: At what plasma osmolarity does <b style="color:red;">AVP</b> release begin? | ~275 mosmol/L.
15. Secretion Threshold: What Sodium level corresponds to the <b style="color:red;">AVP</b> secretion threshold? | ~135 meq/L.
16. Stimuli: List five non-osmotic stimuli for <b style="color:red;">AVP</b> secretion. | 1) Volume loss 2) Nausea <br>3) Hypoglycemia 4) Glucocorticoid deficiency <br>5) Hyperosmolarity
17. Stimuli: What percentage of volume loss is required to stimulate <b style="color:red;">AVP</b>? | >10-20%.
18. Renal Action: To which renal receptors does <b style="color:red;">Arginine Vasopressin</b> bind? | V2 receptors.
19. Renal Action: On which surface of principal cells are <b style="color:red;">V2 receptors</b> located? | Basolateral surface.
20. Renal Action: In which specific renal segments are principal cells found? (2) | Distal tubule; medullary collecting ducts.
21. Aquaporin-2: What does <b style="color:red;">V2 receptor activation</b> trigger the insertion of? | Aquaporin-2 water channels. Inserted into the apical membrane.
22. Metabolism: What is the circulating half-life of <b style="color:red;">AVP</b>? | 10–30 minutes.
23. Metabolism: Which organs are primarily responsible for <b style="color:red;">AVP</b> clearance? (2) | Liver and kidneys.
24. Stimuli: What is the <b style="color:red;">most potent stimulus</b> for AVP secretion? | Nausea.
25. Stimuli: By how much can <b style="color:red;">nausea</b> increase plasma AVP levels? | 50 to 100-fold.
26. Pregnancy: How does <b style="color:blue;">pregnancy</b> affect the metabolic clearance of AVP? | Increases 3-4 fold. Due to placental enzymes.
27. Pregnancy: Which placental enzyme degrades AVP during pregnancy? | N-terminal peptidase.
28. Absence of AVP: What is the permeability of principal cells in the <b style="color:blue;">absence of AVP</b>? | Impermeable to water.
29. Absence of AVP: What is the maximum urine output in the <b style="color:blue;">absence of AVP</b>? | ~0.2 mL/kg/min.
30. Absence of AVP: What is the urine specific gravity when <b style="color:blue;">AVP</b> is absent? | ~1.000.
31. Thirst Osmostat: How is the <b style="color:blue;">thirst osmostat</b> set relative to the AVP osmostat? | 3% higher.
32. Thirst Osmostat: Why is <b style="color:blue;">thirst</b> set higher than the antidiuretic threshold? | Ensure fluid intake. Before dehydration becomes severe.
33. Pituitary DI: What is the most common type of <b style="color:red;">Diabetes Insipidus</b>? | Pituitary (Central) DI.
34. Pituitary DI: What is the primary defect in <b style="color:red;">Central DI</b>? | AVP secretion deficiency.
35. Pituitary DI: Which gene is commonly mutated in hereditary <b style="color:red;">Pituitary DI</b>? | AVP-NPII gene.
36. Nephrogenic DI: What is the primary mechanism of <b style="color:red;">Nephrogenic DI</b>? | Renal insensitivity to AVP.
37. Nephrogenic DI: What is the most common genetic form of <b style="color:red;">Nephrogenic DI</b>? | X-linked V2 receptor mutation.
38. Nephrogenic DI: List two common metabolic/drug causes of <b style="color:red;">Nephrogenic DI</b>. | Lithium and Hypokalemia.
39. Primary Polydipsia: What is the mechanism of <b style="color:red;">Primary Polydipsia</b>? | AVP suppression. Caused by excessive fluid intake.
40. Primary Polydipsia: List three categories of <b style="color:red;">Primary Polydipsia</b>. | Dipsogenic, Psychogenic, and Iatrogenic.
41. Gestational DI: What causes the transient AVP deficiency in <b style="color:red;">Gestational DI</b>? | Placental N-terminal aminopeptidase. Rapidly degrades AVP.
42. Definition: What 24-hour urine volume defines <b style="color:blue;">Diabetes Insipidus</b>? | >40 mL/kg body weight.
43. Definition: What urine osmolarity defines <b style="color:blue;">Diabetes Insipidus</b>? | <280 mosm/L.
44. Clinical Features: What are the two <b style="color:blue;">hallmark symptoms</b> of DI? | Polyuria and polydipsia.
45. Clinical Features: How does polyuria present in <b style="color:red;">Diabetes Insipidus</b>? (2) | Nocturia and enuresis.
46. Dipsogenic DI: What is the primary defect in <b style="color:blue;">Dipsogenic DI</b>? | Abnormally low thirst threshold.
47. Dipsogenic DI: In what clinical scenarios does <b style="color:blue;">Dipsogenic DI</b> often occur? (2) | Head trauma; neurosarcoidosis.
48. Nephrogenic DI: Why does urine remain dilute in <b style="color:red;">Nephrogenic DI</b> despite high AVP? | Kidney non-responsiveness. Inability to respond to the hormone.
49. Diagnostic Step 1: Why is <b style="color:blue;">Exclusion of Glucosuria</b> the first step in DI evaluation? | Rule out Diabetes Mellitus.
50. Diagnostic Evaluation: What does high <b style="color:blue;">Basal Na/Osmolarity</b> rule out? | Primary Polydipsia.
51. Fluid Deprivation Test: What does a failure to concentrate urine after 4-6 hours suggest? | Diabetes Insipidus.
52. Desmopressin Challenge: What is the purpose of the <b style="color:blue;">Desmopressin Challenge</b>? | Distinguish Pituitary vs Nephrogenic DI.
53. Desmopressin Challenge: How does <b style="color:red;">Pituitary DI</b> respond to Desmopressin? | Concentrates urine.
54. Plasma AVP: What is the gold standard test for <b style="color:red;">partial DI defects</b>? | Plasma AVP measurement.
55. Brain MRI: What does the <b style="color:red;">posterior pituitary "bright spot"</b> represent? | Stored AVP.
56. Brain MRI: What is the status of the <b style="color:red;">bright spot</b> in Pituitary DI? | Absent. Usually absent or small.
57. Therapeutic Trial: What happens when <b style="color:blue;">DDAVP</b> is given to a patient with Primary Polydipsia? | Severe hyponatremia. Within 8-24 hours.
58. Therapeutic Trial: Why do patients with <b style="color:red;">Primary Polydipsia</b> develop water intoxication on DDAVP? | Urge to drink persists. While urine output is blocked.
59. Diagnostic Evaluation: When is <b style="color:blue;">Hypertonic saline (3% NaCl)</b> used in DI testing? | Raise plasma osmolarity. To ensure accurate AVP interpretation.
60. Copeptin: What is <b style="color:blue;">Copeptin</b>? | AVP co-secreted peptide. Stable but not currently diagnostic.
61. Pituitary DI Management: What is the first-line treatment for <b style="color:red;">Pituitary DI</b>? | Desmopressin (DDAVP).
62. Pituitary DI Management: Why is <b style="color:blue;">DDAVP</b> preferred over native AVP? (2) | 1) Longer duration <br>2) Lacks V1 pressor effects.
63. Nephrogenic DI Management: List four management strategies for <b style="color:red;">Nephrogenic DI</b>. | 1) Low-sodium diet 2) Thiazides <br>3) Amiloride 4) Indomethacin.
64. Nephrogenic DI Management: What is the pharmacological class of <b style="color:blue;">Indomethacin</b>? | Prostaglandin inhibitor.
65. Primary Polydipsia Management: What is the primary treatment? | Behavioral modification.
66. Primary Polydipsia Management: Why is <b style="color:blue;">DDAVP contraindicated</b> in Primary Polydipsia? | High hyponatremia risk. Water intoxication.
67. DDAVP Therapy: What is the target urine volume goal of <b style="color:blue;">DDAVP</b> treatment? | 15–30 mL/kg/day.
68. DDAVP Therapy: What is the target urine osmolarity goal in <b style="color:blue;">DI management</b>? | 400–800 mOsm/L.
69. Nephrogenic DI Management: How do <b style="color:blue;">Thiazides</b> paradoxically reduce polyuria? | Induce volume depletion. Increases proximal tubule reabsorption.
70. DDAVP Dosing: How do <b style="color:blue;">oral DDAVP</b> doses compare to IV/SC doses? | Significantly higher. (100–400 µg vs 1–2 µg).
71. DDAVP Dosing: Why is the <b style="color:blue;">oral DDAVP</b> dose much higher? | Low bioavailability.
72. Hypodipsic Hypernatremia: What is the definition of <b style="color:blue;">Hypodipsic Hypernatremia</b>? | Hypertonic dehydration. Due to lack of thirst.
73. Hypodipsic Hypernatremia: Where are the destroyed <b style="color:red;">osmoreceptors</b> located? | Anterior hypothalamus.
74. Hypodipsic Hypernatremia: List four <b style="color:blue;">clinical signs</b>. | 1) Tachycardia 2) Azotemia <br>3) Postural hypotension 4) Hyperaldosteronism.
75. Hypodipsic Hypernatremia: What is the metabolic consequence of secondary <b style="color:blue;">hyperaldosteronism</b> in this state? | Hypokalemia.
76. Hypodipsic Hypernatremia: What is the <b style="color:blue;">diagnostic finding</b> in a conscious patient? | Denies thirst. Fails to drink spontaneously.
77. Free Water Deficit: Write the formula for <b style="color:red;">ΔFW</b>. | ΔFW = 0.5 × BW × ([SNa - 140]/140).
78. Hypodipsic Hypernatremia: How does AVP respond to <b style="color:blue;">nausea</b> in this condition? | Responds normally. Confirms neurohypophysis is intact.
79. Hypodipsic Hypernatremia: When is <b style="color:blue;">DDAVP</b> used in this condition? | Concurrent Pituitary DI. To complete rehydration.
80. SIADH: What is the core definition of <b style="color:blue;">SIADH</b>? | Hypo-osmolemic hyponatremia. Inappropriate AVP secretion.
81. NSIAD: What causes <b style="color:red;">Nephrogenic SIAD (NSIAD)</b>? | Activating V2 mutations. Constantly active receptor.
82. Type I Hyponatremia: What conditions cause <b style="color:red;">Hypervolemic hyponatremia</b>? (3) | CHF, cirrhosis, or nephrosis.
83. Type I Hyponatremia: What characterizes the physical exam in <b style="color:blue;">Hypervolemic</b> cases? | Generalized edema.
84. Type II Hyponatremia: What characterizes <b style="color:red;">Hypovolemic hyponatremia</b>? | Sodium/water loss. Or Addison’s disease.
85. Type II Hyponatremia: List two laboratory findings in <b style="color:blue;">Hypovolemic</b> hyponatremia. | Hypotension and high PRA.
86. Type III Hyponatremia: What is <b style="color:red;">Type III hyponatremia</b>? | Euvolemic hyponatremia. Includes classic SIADH/NSIAD.
87. Pathophysiology: Why is <b style="color:blue;">edema absent</b> in SIADH? | Natriuresis occurs. Suppression of Renin and Aldosterone.
88. Symptoms: What causes the symptoms in <b style="color:blue;">SIADH</b>? | Brain swelling. Move water into cells from increased ICP.
89. Treatment: What are <b style="color:blue;">Vaptans</b> (V2-receptor antagonists) used for? | Euvolemic hyponatremia. Severe or symptomatic.
90. Vaptans: Give two examples of <b style="color:blue;">Vaptans</b> and their routes. | Tolvaptan (oral); Conivaptan (IV).
91. Chronic SIADH: Why do symptoms eventually subside in <b style="color:blue;">chronic SIADH</b>? | Solute inactivation. Brain reduces its own cellular volume.
92. Management: How is <b style="color:blue;">Hypervolemic Hyponatremia</b> treated? | Fluid restriction.
93. Management: Why is <b style="color:red;">Hypertonic saline contraindicated</b> in Hypervolemic Hyponatremia? | Worsens edema. And heart failure.
94. Management: How is <b style="color:blue;">Hypovolemic Hyponatremia</b> replaced? | Isotonic or Hypertonic saline.
95. Management: What is <b style="color:red;">contraindicated</b> in Hypovolemic Hyponatremia? | Fluid restriction.
96. Severe Euvolemic SIADH: What is the acute treatment? | 3% Hypertonic Saline.
97. Target Rate: What is the target rate of Na rise in <b style="color:blue;">acute hyponatremia</b>? | ~1% per hour.
98. Target Rate: At what Na level should <b style="color:blue;">acute hyponatremia</b> treatment stop? | ~130 meq/L.
99. Complication: What is the risk of <b style="color:red;">rapid sodium correction</b>? | Osmotic Demyelination. (Central Pontine Myelinolysis).
100. Central Pontine Myelinolysis: What are the primary symptoms? (2) | Quadriparesis and ataxia.
101. NSIAD treatment: What is used if <b style="color:blue;">Vaptans fail</b> in NSIAD? | Urea. An osmotic diuretic.
102. Monitoring: What must be closely monitored during <b style="color:blue;">Tolvaptan</b> use? | Fluid intake. To avoid over-correction/hypernatremia.
103. Comparison: How does the <b style="color:blue;">Desmopressin response</b> differ in Pituitary vs Nephrogenic DI? | Pituitary: Urine concentrates. Nephrogenic: Minimal response.
104. Comparison: How does <b style="color:blue;">MRI</b> distinguish DI from Polydipsia? | Bright Spot. Present in Polydipsia; Absent in DI.
105. Comparison: What is the <b style="color:blue;">Natremia outcome</b> of DDAVP in Primary Polydipsia? | Hyponatremia. (Rapidly occurs).
106. Comparison: What is the key physical finding in <b style="color:blue;">SIADH vs. Hypervolemic Hyponatremia</b>? | Edema. Present in Hypervolemic; Absent in SIADH.
107. Comparison: How does <b style="color:blue;">Addison's</b> differ from Secondary Adrenal Insufficiency in electrolytes? | Primary (Addison’s): High K. (Loses Aldosterone).
108. Comparison: What is the <b style="color:blue;">volume status</b> in Hypodipsic hypernatremia vs Excess Salt intake? | Hypodipsia: Hypovolemia. Excess salt: Hypervolemia.
109. Comparison: How does <b style="color:blue;">Gestational DI</b> differ from Central DI timing? | Gestational: Pregnancy only. Remits postpartum.
110. Comparison: How do <b style="color:blue;">AVP levels</b> differ in SIADH vs NSIAD? | SIADH: Elevated AVP. NSIAD: Undetectable AVP.
111. Comparison: Which is more sensitive: <b style="color:blue;">AVP or Thirst</b>? | AVP osmostat. Responds first to preserve water.
112. Comparison: How does the <b style="color:blue;">Thirst osmostat</b> threshold compare to AVP? | 3% higher.
113. Comparison: What is the action of <b style="color:blue;">V1 receptors</b>? | Vasoconstriction. (Pressor effect).
114. Comparison: What is the action of <b style="color:blue;">V2 receptors</b>? | Water reabsorption. In the kidney.
115. Hormone Storage: What term describes the bulbous axonal enlargements in the <b style="color:blue;">Neurohypophysis</b>? | Termination of axons. Store and release hormones.
116. AVP Physiology: Where are <b style="color:red;">Aquaporin-2</b> channels specifically inserted? | Apical membrane. For water reabsorption.
117. Metabolism: How many fold can <b style="color:red;">nausea</b> increase AVP levels? | 50 to 100-fold.
118. DI Etiology: What condition is a <b style="color:red;">Dipsogenic DI</b> usually following? (1) | Head trauma. Or neurosarcoidosis.
119. Diagnostic Evaluation: What does the <b style="color:blue;">Posterior Pituitary "bright spot"</b> reflect on T1-weighted MRI? | Stored Vasopressin.
120. Management: What is the target <b style="color:blue;">urine osmolarity</b> for effective DDAVP therapy? | 400–800 mOsm/L.


# 10
## Summary
```text
### Thyroid Gland Physiology and Testing

*   <b>Thyroid Hormones:</b> The thyroid gland produces thyroxine (T4) and triiodothyronine (T3), which act via thyroid hormone receptors (TR) α and β to maintain thermogenic and metabolic homeostasis.
*   <b>C Cells:</b> Derived from the neural crest, C cells produce calcitonin and are the origin of medullary thyroid cancer, though they play a minimal role in human calcium homeostasis.
*   <b>Thyroid Stimulating Hormone (TSH):</b> Secreted by anterior pituitary thyrotrope cells, TSH is the most useful physiologic marker of thyroid hormone action and exhibits a pulsatile, diurnal rhythm with peak levels at night.
*   <b>TSH Structure:</b> TSH is a 31-kDa glycoprotein sharing an α subunit with LH, FSH, and hCG; its unique β subunit determines specificity.
*   <b>Negative Feedback:</b> Thyroid hormones exert negative feedback on TRH and TSH primarily via the TRβ2 receptor.
*   <b>TSH Suppression:</b> Dopamine, glucocorticoids, and somatostatin can suppress TSH levels, which is clinically relevant mainly at high doses.
*   <b>Iodine Metabolism:</b> Iodide uptake is the rate-limiting step in thyroid hormone synthesis, mediated by the sodium-iodide symporter (NIS) on the basolateral membrane.
*   <b>NIS Regulation:</b> NIS expression is upregulated by iodine deficiency and downregulated by iodine excess.
*   <b>Iodine Efflux:</b> Pendrin, an iodine transporter on the apical surface, mediates iodine efflux into the lumen; mutations cause Pendred syndrome (goiter and sensorineural deafness).
*   <b>Organification and Coupling:</b> Thyroid peroxidase (TPO) oxidizes iodide using H₂O₂ and catalyzes the coupling of MIT and DIT to produce T3 or T4.
*   <b>Wolff-Chaikoff Effect:</b> Excess iodide transiently inhibits thyroid iodide organification.
*   <b>Cretinism:</b> Characterized by intellectual disability and growth retardation, cretinism is typically associated with congenital hypothyroidism.
*   <b>Dietary Iodine RDA:</b> The recommended dietary allowance for iodine is 220 μg/day for pregnancy and 290 μg/day for breastfeeding.

### Thyroid Function in Pregnancy

*   <b>hCG Stimulation:</b> During the first trimester, a transient increase in hCG weakly stimulates the TSH receptor, leading to a reciprocal fall in TSH.
*   <b>Thyroxine-Binding Globulin (TBG):</b> Estrogen induces a rise in TBG during the 1st trimester that is sustained throughout pregnancy, increasing total T4 and T3 levels while free levels remain normal.
*   <b>Iodine Excretion in Pregnancy:</b> Increased urinary iodide excretion and placental type III deiodinase activity can impair thyroid hormone production in areas of marginal iodine sufficiency.
*   <b>Levothyroxine in Pregnancy:</b> Treated hypothyroid women typically require a dose increase of up to 45% during pregnancy.
*   <b>TSH Screening in Pregnancy:</b> TSH testing is recommended for women planning pregnancy if they have a family history of autoimmune thyroid disease, type 1 diabetes, infertility, prior preterm delivery, or are older than 30.
*   <b>Free T4 in Pregnancy:</b> Free T4 levels may slightly increase in the first trimester but decrease progressively; 3rd-trimester values may fall below nonpregnant lower limits.

### Thyroid Hormone Transport and Metabolism

*   <b>T4 vs. T3 Half-life:</b> Thyroxine (T4) has a significantly longer half-life (7 days) compared to triiodothyronine (T3) (2 days).
*   <b>Thyroid Secretion Fraction:</b> 100% of circulating T4 is secreted directly by the thyroid, whereas only 20% of T3 is secreted by the gland; 80% of T3 comes from peripheral conversion.
*   <b>Potency:</b> T3 is metabolically more potent and active compared to T4.
*   <b>Type I Deiodinase:</b> Found in the thyroid, liver, and kidneys; it has a relatively low affinity for T4.
*   <b>Type II Deiodinase:</b> Found in the pituitary, brain, and brown fat; it has a higher affinity for T4 and regulates local T3 concentrations.
*   <b>Type III Deiodinase:</b> Expressed in the human placenta, muscle, and liver; it inactivates T4 and T3 and is the most important source of reverse T3 (rT3).
*   <b>T4 to T3 Conversion Inhibitors:</b> Peripheral conversion is impaired by fasting, systemic illness, trauma, oral contrast, PTU, propranolol, amiodarone, and glucocorticoids.
*   <b>MCT8 and MCT10:</b> Specific transporters that allow circulating thyroid hormones to enter cells.
*   <b>Resistance to Thyroid Hormone (RTH):</b> An autosomal dominant disorder with elevated thyroid hormones and inappropriately normal/elevated TSH; common features include goiter, ADHD, and tachycardia.

### Laboratory and Physical Evaluation

*   <b>Normal Thyroid Size:</b> The thyroid gland normally weighs 12–20 grams and should move upon swallowing.
*   <b>Bruit/Thrill:</b> Indicates increased vascularity and is associated with hyperthyroidism.
*   <b>Pemberton’s Sign:</b> Venous distention over the neck and difficulty breathing when arms are raised; indicates a large retrosternal goiter.
*   <b>Biotin Interference:</b> Biotin supplements can cause falsely low TSH and falsely high T4/T3; patients should stop biotin for at least 2 days before testing.
*   <b>TSH Sensitivity:</b> Assays sensitive to ≤ 0.1 mIU/L are sufficient for most clinical purposes.
*   <b>Primary Hyperthyroidism Lab:</b> Characterized by low TSH and high Free T4.
*   <b>Secondary TSH Lab:</b> Pituitary/hypothalamic disease presents with low T4 and inappropriately low or normal TSH.
*   <b>Thyroid-Stimulating Immunoglobulins (TSI):</b> Antibodies that stimulate the TSH receptor in Graves' disease; measured by TRAb assays.
*   <b>Serum Thyroglobulin (Tg):</b> Tg is increased in all types of thyrotoxicosis except thyrotoxicosis factitia; it is a vital marker for thyroid cancer recurrence (target <0.20 ng/mL).
*   <b>Radioiodine Uptake (RAIU):</b> High/homogeneous in Graves; focal in toxic adenoma; low/absent in thyroiditis and factitious thyrotoxicosis.
*   <b>"Hot" vs. "Cold" Nodules:</b> Hot nodules (functioning) are almost never malignant; cold nodules (non-functioning) have a 5-10% malignancy risk.
*   <b>Ultrasound Malignancy Signs:</b> Hypoechoic solid nodules with infiltrative borders and microcalcifications suggest a >90% cancer risk.

### Hypothyroidism

| Category | Key Features | Diagnosis | Treatment |
| :--- | :--- | :--- | :--- |
| **Congenital** | Occurs in 1:2000-4000; majority appear normal at birth; risk of permanent neurologic damage. | Neonatal screening (heel prick) for TSH/T4; Thyroid dysgenesis is the #1 cause (65%). | Levothyroxine 10-15 µg/kg/day started early to ensure normal IQ. |
| **Hashimoto's** | Most common cause in iodine-sufficient areas; lymphocytic infiltration; firm/irregular goiter. | Elevated TSH, (+) TPO/Tg antibodies (>95%); Heterogeneous echogenicity on US. | Standard LT4 1.6 µg/kg/day; take 30 min before breakfast. |
| **Atrophic** | End-stage Hashimoto's; extensive fibrosis; minimal residual thyroid tissue. | Elevated TSH, low FT4; IgG4-positive plasma cells may be present. | Standard replacement with LT4. |
| **Myxedema Coma** | Life-threatening; 20-40% mortality; reduced consciousness, hypothermia, seizures. | Clinical diagnosis in severe hypothyroidism; impaired adrenal reserve. | IV LT4 bolus (200-400 µg) + Hydrocortisone; external warming only if <30ºC. |

*   <b>Hypothyroidism Symptoms:</b> Include dry skin, nonpitting edema (myxedema), constipation, weight gain (fluid), bradycardia, and delayed tendon reflex relaxation.
*   <b>Overt Hypothyroidism:</b> Defined by an elevated TSH (usually >10 mIU/L) and low unbound T4.
*   <b>Subclinical Hypothyroidism:</b> Elevated TSH with normal unbound T4; treat if TSH >10, if the patient is pregnant, or wishes to conceive.
*   <b>Elderly/CAD Treatment:</b> Start LT4 at a low dose (12.5–25 µg/day) to avoid provoking heart failure or arrhythmias.
*   <b>Secondary Hypothyroidism:</b> Confirmed by low unbound T4 with a low or inappropriately normal TSH.
*   <b>Hashimoto’s Encephalopathy:</b> A steroid-responsive syndrome associated with TPO antibodies, myoclonus, and slow-wave EEG activity.

### Hyperthyroidism and Thyrotoxicosis

| Entity | Pathogenesis | Unique Findings | Treatment |
| :--- | :--- | :--- | :--- |
| **Graves’ Disease** | TSI/TRAb antibodies stimulate the TSH-R; accounts for 60-80% of thyrotoxicosis. | Exophthalmos, Pretibial myxedema, Bruit/Thrill; NO SPECS scoring for eyes. | Antithyroid drugs (Methimazole/PTU), Radioiodine (131I), or Surgery. |
| **Thyroid Storm** | Life-threatening exacerbation; precipitated by illness, surgery, or radioiodine. | Fever, delirium, jaundice, vomiting, high-output heart failure. | High dose PTU (blocks T4->T3), Iodide (1hr after PTU), Propranolol, Steroids. |
| **Toxic MNG** | Functioning nodules in an enlarged/distorted gland. | Distorted architecture with multiple "hot" and "cold" areas on scan. | Radioiodine or Surgery. |
| **AIT Type 1** | Iodine load (Jod-Basedow) in underlying Grave's/MNG. | Increased vascularity on Doppler US. | High-dose antithyroid drugs; Potassium perchlorate. |
| **AIT Type 2** | Destructive thyroiditis caused by amiodarone. | Decreased vascularity on Doppler US. | Glucocorticoids (Prednisone 40mg). |

*   <b>Antithyroid Drugs (Thionamides):</b> Methimazole is generally preferred due to its longer half-life; PTU is preferred in the first trimester of pregnancy and thyroid storm (inhibits T4 to T3 conversion).
*   <b>Radioiodine Contraindication:</b> 131I is absolutely contraindicated in pregnancy and breastfeeding.
*   <b>Apathetic Thyrotoxicosis:</b> Presentation in the elderly where symptoms are subtle, appearing as fatige, weight loss, and atrial fibrillation.
*   <b>SSKI (Potassium Iodide):</b> Used pre-operatively in Graves' to reduce gland vascularity via the Wolff-Chaikoff effect.

### Thyroiditis

*   <b>Acute Thyroiditis:</b> A suppurative infection (often left-sided) usually caused by a piriform sinus remnant; thyroid function is normal, but ESR and WBC are high.
*   <b>Subacute Thyroiditis (de Quervain’s):</b> A painful, viral-mediated inflammation with three phases (Thyrotoxic, Hypothyroid, Recovery); ESR is very high (>50) and radioiodine uptake is low (<5%).
*   <b>Subacute Thyroiditis Treatment:</b> Large doses of aspirin or NSAIDs; glucocorticoids (Prednisone 15-40mg) if NSAIDs are inadequate.
*   <b>Silent Thyroiditis:</b> Painless autoimmune thyroiditis; symptoms are managed with propranolol; differs from subacute by having normal ESR and (+) TPO antibodies.
*   <b>Postpartum Thyroiditis:</b> A form of silent thyroiditis occurring 3–6 months after delivery in 5% of women; common in T1DM.
*   <b>Riedel’s Thyroiditis:</b> A hard, fixed, "woody" goiter linked to IgG4-related disease; may require biopsy to distinguish from malignancy; tamoxifen may benefit.

### Comparison / Differentiation of Key Entities

*   <b>Subacute vs. Silent Thyroiditis:</b> Subacute thyroiditis is painful with a high ESR; Silent thyroiditis is painless with a normal ESR and (+) TPO antibodies.
*   <b>Graves’ Disease vs. Subacute Thyroiditis:</b> Graves shows high radioiodine uptake and high T3/T4 ratio; Subacute thyroiditis shows low radioiodine uptake and a lower T3/T4 ratio (T4 is higher).
*   <b>Primary vs. Secondary Hyperthyroidism:</b> In Primary, TSH is low and T3/T4 are high. In Secondary (pituitary tumor), both TSH and T3/T4 are high.
*   <b>Type 1 vs. Type 2 Amiodarone-Induced Thyrotoxicosis (AIT):</b> Type 1 is hyperthyroidism (high vascularity on Doppler); Type 2 is thyroiditis (low vascularity on Doppler).
*   <b>T4 vs. T3 Half-life and Potency:</b> T4 has a 7-day half-life and is a pro-hormone; T3 has a 2-day half-life and is the active, potent form.
*   <b>Hypothyroid vs. RTH:</b> Hypothyroidism has high TSH and low T4; Resistance to Thyroid Hormone (RTH) has high/normal TSH and high T4.
*   <b>Sick Euthyroid vs. True Hypothyroidism:</b> Both have low T3, but Sick Euthyroid has high reverse T3 (rT3) and usually a normal TSH, whereas Hypothyroidism has low rT3 and high TSH.
*   <b>T3 Toxicosis vs. T4 Toxicosis:</b> T3 toxicosis (2-5% of Graves) has high T3 and normal T4. T4 toxicosis (iodine excess) has high T4 and normal T3.
*   <b>Biotin vs. Hyperthyroidism Labs:</b> Both can show low TSH and high T4/T3. Differentiate by history of supplement use and stopping biotin for 2 days.
*   <b>Hashimoto's vs. Atrophic Thyroiditis:</b> Hashimoto's is goitrous (firm/irregular); Atrophic is the end-stage without a palpable gland and extensive fibrosis.
*   <b>Methimazole vs. PTU:</b> Methimazole has a longer half-life (6 hrs vs 90 min) and is once-daily. PTU is used in thyroid storm and 1st trimester pregnancy due to T4->T3 block and lower teratogenicity.
*   <b>Iodine Deficiency vs. Excess (Wolff-Chaikoff):</b> Deficiency upregulates NIS to increase uptake; Excess transiently shuts down organification (Wolff-Chaikoff).
*   <b>Pregnancy TSH vs. Non-pregnant TSH:</b> First trimester TSH is lower than non-pregnant due to hCG stimulation; second to third trimester usually returns to non-pregnant ranges.
*   <b>Type II vs. Type III Deiodinase:</b> Type II converts T4 to T3 (activation); Type III converts T4/T3 into inactive forms/rT3 (inactivation).
*   <b>Pemberton’s Sign vs. NO SPECS:</b> Pemberton’s assesses retrosternal goiter compression; NO SPECS evaluates the severity of Graves' ophthalmopathy.
```

## QA

```text
### Thyroid Gland Physiology and Testing

1. What receptors do <b style="color:red">Thyroid Hormones</b> (T4 and T3) act via to maintain homeostasis? | TR α and β
2. What is the embryonic origin of <b style="color:red">C Cells</b>? | Neural crest
3. What protein is produced by <b style="color:red">C Cells</b>? | Calcitonin
4. From which cells does <b style="color:red">Medullary Thyroid Cancer</b> originate? | C cells
5. What is the most useful physiologic marker of <b style="color:red">Thyroid Hormone</b> action? | TSH
6. When do <b style="color:red">TSH levels</b> typically reach their peak in the diurnal rhythm? | Night
7. What are the shared and unique subunits of <b style="color:red">TSH</b>? | α (shared); β (unique)
8. Which hormones share the same α subunit as <b style="color:red">TSH</b>? (3) | LH, FSH, and hCG
9. Through which specific receptor do thyroid hormones exert <b style="color:red">Negative Feedback</b> on TRH and TSH? | TRβ2 receptor
10. Which substances can suppress <b style="color:red">TSH levels</b> at high doses? (3) | Dopamine, glucocorticoids, somatostatin
11. What is the rate-limiting step in <b style="color:red">Thyroid Hormone Synthesis</b>? | Iodide uptake
12. Which transporter on the basolateral membrane mediates <b style="color:red">Iodide Uptake</b>? | Sodium-iodide symporter (NIS)
13. How does <b style="color:red">Iodine Deficiency</b> affect NIS expression? | Upregulates expression
14. How does <b style="color:red">Iodine Excess</b> affect NIS expression? | Downregulates expression
15. What apical transporter mediates <b style="color:red">Iodine Efflux</b> into the lumen? | Pendrin
16. What are the clinical features (2) of <b style="color:red">Pendred Syndrome</b>? | Goiter and sensorineural deafness
17. Which enzyme oxidizes iodide and catalyzes the coupling of <b style="color:red">MIT and DIT</b>? | Thyroid peroxidase (TPO)
18. What is the <b style="color:red">Wolff-Chaikoff Effect</b>? | Excess iodide inhibits organification
19. What are the characteristics (2) of <b style="color:red">Cretinism</b>? | Intellectual disability; growth retardation
20. What is the RDA for <b style="color:red">Iodine</b> during pregnancy? | 220 μg/day
21. What is the RDA for <b style="color:red">Iodine</b> during breastfeeding? | 290 μg/day

### Thyroid Function in Pregnancy

22. Why does <b style="color:red">TSH</b> fall reciprocally during the first trimester of pregnancy? | hCG stimulates TSH-R
23. What effect does estrogen have on <b style="color:red">Thyroxine-Binding Globulin (TBG)</b> in pregnancy? | Induces a rise
24. How do total T4/T3 levels change in pregnancy compared to <b style="color:red">Free T4/T3</b>? | Total increases; Free normal
25. Which enzyme in the placenta can impair <b style="color:red">Thyroid Hormone production</b>? | Type III deiodinase
26. What is the typical dose increase for <b style="color:red">Levothyroxine</b> required during pregnancy? | Up to 45%
27. What are the criteria for <b style="color:red">TSH Screening</b> in pregnancy? (5) | 1) Autoimmune history<br>2) Type 1 Diabetes<br>3) Infertility<br>4) Preterm delivery<br>5) Age >30
28. Describe the trend of <b style="color:red">Free T4</b> during the third trimester of pregnancy. | May fall below limits

### Thyroid Hormone Transport and Metabolism

29. Compare the half-life of <b style="color:red">Thyroxine (T4)</b> vs. Triiodothyronine (T3). | T4 (7 days) > T3 (2 days)
30. What percentage of circulating <b style="color:red">T4</b> is secreted directly by the thyroid? | 100%
31. What percentage of circulating <b style="color:red">T3</b> comes from peripheral conversion? | 80%
32. Which thyroid hormone is metabolically more <b style="color:red">Potent</b>? | T3
33. Where is <b style="color:red">Type I Deiodinase</b> primarily found? (3) | Thyroid, liver, and kidneys
34. Which deiodinase regulates local <b style="color:red">T3 concentrations</b> in the pituitary and brain? | Type II Deiodinase
35. Which deiodinase is the most important source of <b style="color:red">reverse T3 (rT3)</b>? | Type III Deiodinase
36. Where is <b style="color:red">Type III Deiodinase</b> expressed? (3) | Placenta, muscle, and liver
37. What drugs/factors inhibit <b style="color:red">T4 to T3 conversion</b>? (8) | Fasting, illness, trauma, contrast, PTU, propranolol, amiodarone, glucocorticoids
38. What are <b style="color:red">MCT8 and MCT10</b>? | Specific thyroid hormone transporters
39. What is the inheritance pattern of <b style="color:red">Resistance to Thyroid Hormone (RTH)</b>? | Autosomal dominant
40. What are the lab findings in <b style="color:red">Resistance to Thyroid Hormone (RTH)</b>? | High T4; normal/high TSH
41. What are the common features (3) of <b style="color:red">Resistance to Thyroid Hormone (RTH)</b>? | Goiter, ADHD, and tachycardia

### Laboratory and Physical Evaluation

42. What is the <b style="color:red">Normal Thyroid Weight</b> in an adult? | 12–20 grams
43. What does a <b style="color:red">Thyroid Bruit/Thrill</b> indicate? | Increased vascularity
44. What is <b style="color:red">Pemberton’s Sign</b>? | Venous distention upon raising arms
45. What does a positive <b style="color:red">Pemberton’s Sign</b> indicate? | Retrosternal goiter
46. How does <b style="color:red">Biotin</b> interfere with thyroid labs? | Low TSH; high T4/T3
47. How long should <b style="color:red">Biotin</b> be stopped before testing? | At least 2 days
48. What lab profile defines <b style="color:red">Primary Hyperthyroidism</b>? | Low TSH; high Free T4
49. What lab profile defines <b style="color:red">Secondary (Central) Hypothyroidism</b>? | Low T4; low/normal TSH
50. What antibodies are measured by <b style="color:red">TRAb assays</b> to diagnose Graves' disease? | Thyroid-Stimulating Immunoglobulins (TSI)
51. When is <b style="color:red">Serum Thyroglobulin (Tg)</b> decreased in the setting of thyrotoxicosis? | Thyrotoxicosis factitia
52. What is the follow-up target for <b style="color:red">Thyroglobulin</b> in thyroid cancer recurrence? | <0.20 ng/mL
53. Describe the <b style="color:red">Radioiodine Uptake (RAIU)</b> in Graves' disease. | High and homogeneous
54. Describe the <b style="color:red">Radioiodine Uptake (RAIU)</b> in Thyroiditis. | Low or absent
55. What is the malignancy risk of a <b style="color:red">"Hot" (functioning) Nodule</b>? | Almost never malignant
56. What is the malignancy risk of a <b style="color:red">"Cold" Nodule</b>? | 5-10%
57. What ultrasound signs (3) suggest <b style="color:red">Thyroid Malignancy</b> (>90% risk)? | Hypoechoic, infiltrative borders, microcalcifications

### Hypothyroidism

58. What is the incidence of <b style="color:red">Congenital Hypothyroidism</b>? | 1:2000-4000
59. What is the #1 cause of <b style="color:red">Congenital Hypothyroidism</b>? | Thyroid dysgenesis (65%)
60. What is the screening method for <b style="color:red">Neonatal Hypothyroidism</b>? | Heel prick (TSH/T4)
61. What is the treatment dose for <b style="color:red">Congenital Hypothyroidism</b>? | Levothyroxine 10-15 µg/kg/day
62. What is the most common cause of <b style="color:red">Hypothyroidism</b> in iodine-sufficient areas? | Hashimoto's Thyroiditis
63. What are the key lab findings (2) in <b style="color:red">Hashimoto's Thyroiditis</b>? | High TSH; (+) TPO/Tg antibodies
64. What is the standard dose and timing for <b style="color:red">Levothyroxine (LT4)</b>? | 1.6 µg/kg; 30 min before breakfast
65. What defines <b style="color:red">Atrophic Thyroiditis</b>? | Fibrosis and minimal residual tissue
66. What antibody-containing cells may be present in <b style="color:red">Atrophic Thyroiditis</b>? | IgG4-positive plasma cells
67. What are the clinical signs (3) of <b style="color:red">Myxedema Coma</b>? | Low consciousness, hypothermia, seizures
68. What is the mortality rate of <b style="color:red">Myxedema Coma</b>? | 20-40%
69. What is the initial pharmacological treatment for <b style="color:red">Myxedema Coma</b>? | IV LT4 + Hydrocortisone
70. What are the classic physical exam findings (4) of <b style="color:red">Hypothyroidism</b>? | Dry skin, myxedema, bradycardia, delayed reflexes
71. What defines <b style="color:red">Overt Hypothyroidism</b> lab-wise? | High TSH; low unbound T4
72. What defines <b style="color:red">Subclinical Hypothyroidism</b>? | High TSH; normal unbound T4
73. When should <b style="color:red">Subclinical Hypothyroidism</b> be treated? (3) | TSH >10, pregnant, or desiring conception
74. What is the starting dose of <b style="color:red">LT4</b> in the elderly or those with CAD? | 12.5–25 µg/day
75. What is <b style="color:red">Hashimoto’s Encephalopathy</b>? | Steroid-responsive syndrome with TPO antibodies

### Hyperthyroidism and Thyrotoxicosis

76. What percentage of thyrotoxicosis is caused by <b style="color:red">Graves' Disease</b>? | 60-80%
77. What are the unique physical findings (3) of <b style="color:red">Graves' Disease</b>? | Exophthalmos, pretibial myxedema, bruit
78. What scoring system is used for <b style="color:red">Graves' Ophthalmopathy</b>? | NO SPECS
79. What are the life-threatening symptoms (4) of <b style="color:red">Thyroid Storm</b>? | Fever, delirium, jaundice, heart failure
80. What is the purpose of <b style="color:red">PTU</b> in Thyroid Storm? | Blocks T4 to T3 conversion
81. In <b style="color:red">Thyroid Storm</b>, when should iodide be administered? | 1 hour after PTU
82. What is the characteristic appearance of <b style="color:red">Toxic Multinodular Goiter (MNG)</b> on scan? | Multiple "hot" and "cold" areas
83. What defines <b style="color:red">Amiodarone-Induced Thyrotoxicosis (AIT) Type 1</b>? | Jod-Basedow effect (iodine load)
84. How is <b style="color:red">AIT Type 2</b> distinguished from Type 1 on Doppler? | Type 2 has decreased vascularity
85. What is the treatment for <b style="color:red">AIT Type 2</b>? | Glucocorticoids (Prednisone)
86. Why is <b style="color:red">Methimazole</b> generally preferred over PTU? | Longer half-life (once-daily)
87. When is <b style="color:red">PTU</b> specifically preferred over Methimazole? (2) | 1st trimester; Thyroid Storm
88. What is the absolute contraindication for <b style="color:red">Radioiodine (131I)</b>? | Pregnancy and breastfeeding
89. What is <b style="color:red">Apathetic Thyrotoxicosis</b>? | Subtle presentation in the elderly
90. Why is <b style="color:red">SSKI</b> given pre-operatively in Graves'? | Reduces gland vascularity

### Thyroiditis

91. What is the most common cause of <b style="color:red">Acute Thyroiditis</b>? | Piriform sinus remnant
92. Which phase of <b style="color:red">Subacute (de Quervain’s) Thyroiditis</b> follows the thyrotoxic phase? | Hypothyroid phase
93. What are the typical lab findings in <b style="color:red">Subacute Thyroiditis</b>? | High ESR (>50); RAIU <5%
94. What is the first-line treatment for <b style="color:red">Subacute Thyroiditis</b>? | Aspirin or NSAIDs
95. How does <b style="color:red">Silent Thyroiditis</b> differ from subacute regarding labs? | Normal ESR; (+) TPO antibodies
96. When does <b style="color:red">Postpartum Thyroiditis</b> typically occur? | 3–6 months after delivery
97. What disease is <b style="color:red">Riedel’s Thyroiditis</b> linked to? | IgG4-related disease
98. What is the characteristic feel of the gland in <b style="color:red">Riedel’s Thyroiditis</b>? | Hard, fixed, "woody" goiter

### Comparisons and Differentiations

99. Compare <b style="color:red">Subacute vs. Silent Thyroiditis</b> (pain and ESR). | Subacute: Painful/High ESR;<br>Silent: Painless/Normal ESR
100. Compare <b style="color:red">Graves vs. Subacute Thyroiditis</b> in terms of RAIU. | Graves: High uptake;<br>Subacute: Low uptake
101. Compare <b style="color:red">Primary vs. Secondary Hyperthyroidism</b> (TSH level). | Primary: Low TSH;<br>Secondary: High TSH
102. Compare <b style="color:red">Vascularity</b> in AIT Type 1 vs. Type 2. | Type 1: High vascularity;<br>Type 2: Low vascularity
103. Compare the potency and half-life of <b style="color:red">T4 vs. T3</b>. | T4: Longer half-life;<br>T3: More potent
104. Compare <b style="color:red">Hypothyroidism vs. RTH</b> lab profiles. | Hypothyroid: High TSH/Low T4;<br>RTH: High-Normal TSH/High T4
105. How does <b style="color:red">Sick Euthyroid</b> differ from Hypothyroidism regarding rT3? | Sick Euthyroid: High rT3;<br>Hypothyroidism: Low rT3
106. What defines <b style="color:red">T3 Toxicosis</b> lab values? | High T3; normal T4
107. How can <b style="color:red">Biotin interference</b> be clinicaly differentiated from Hyperthyroidism? | 2-day supplement cessation
108. Compare <b style="color:red">Hashimoto's vs. Atrophic Thyroiditis</b> exam findings. | Hashimoto's: Goiter;<br>Atrophic: No palpable gland
109. Compare the mechanism of <b style="color:red">Iodine Deficiency vs. Excess</b> on NIS. | Deficiency: Upregulates NIS;<br>Excess: Downregulates NIS
110. Compare <b style="color:red">Type II vs. Type III Deiodinase</b> function. | Type II: Activates (T4->T3);<br>Type III: Inactivates
111. Contrast <b style="color:red">Pemberton's Sign vs. NO SPECS</b> utility. | Pemberton’s: Retrosternal goiter;<br>NO SPECS: Ophthalmopathy
```

# 11
## Summary
```text
### Adrenal Anatomy, Development, and Regulation

- <b style="color:red">Adrenal Cortex Layers</b>: The adrenal cortex is organized into three zones: the outer <i style="color:blue">zona glomerulosa</i> (produces mineralocorticoids like aldosterone), the middle <i style="color:blue">zona fasciculata</i> (produces glucocorticoids like cortisol), and the inner <i style="color:blue">zona reticularis</i> (produces adrenal androgen precursors like DHEA).
- <b style="color:red">Adrenal Gland Weight</b>: Normal adult adrenal glands weigh between 6–11 g each.
- <b style="color:red">Embryonic Origin</b>: Adrenals originate from the urogenital ridge, separating from the gonads and kidneys at approximately the sixth week of gestation.
- <b style="color:red">Fetal Steroidogenesis</b>: The adrenal cortex begins producing cortisol and DHEA between the seventh and ninth weeks of gestation, coinciding with sexual differentiation.
- <b style="color:red">Glucocorticoid/Androgen Regulation</b>: Cortisol and adrenal androgens are regulated by the <i style="color:blue">Hypothalamic-Pituitary-Adrenal (HPA) axis</i> via CRH and ACTH, featuring inhibitory negative feedback.
- <b style="color:red">Mineralocorticoid Regulation</b>: Aldosterone is primarily regulated by the <i style="color:blue">Renin-Angiotensin-Aldosterone System (RAAS)</i> and serum potassium levels, rather than the HPA axis.
- <b style="color:red">RAAS Activation</b>: Decreased renal perfusion pressure stimulates <i style="color:blue">juxtaglomerular cells</i> to release renin, which converts angiotensinogen to angiotensin I; ACE then converts it to <i style="color:blue">Angiotensin II</i>, which triggers aldosterone secretion via the AT1 receptor.

### Steroid Hormone Synthesis and Action

- <b style="color:red">Rate-Limiting Step</b>: The transport of cholesterol into the mitochondria via the <i style="color:blue">Steroidogenic Acute Regulatory (StAR) protein</i> is the rate-limiting step in steroidogenesis.
- <b style="color:red">ACTH Signaling</b>: ACTH binds to the <i style="color:blue">MC2R receptor</i> (requiring MRAP for trafficking), increasing cAMP and PKA to initiate steroidogenesis.
- <i style="color:blue">Key Steroidogenic Enzymes Table</i>:
| Enzyme | Function | Pathway Impact |
| :--- | :--- | :--- |
| <b>CYP11A1</b> | Side chain cleavage (Cholesterol → Pregnenolone) | All steroids |
| <b>3β-HSD2</b> | Pregnenolone → Progesterone | All pathways |
| <b>CYP17A1</b> | 17α-hydroxylase/17,20 lyase | Cortisol and Androgens |
| <b>CYP21A2</b> | 21-hydroxylation | Cortisol and Aldosterone |
| <b>CYP11B1</b> | 11β-hydroxylation | Cortisol (Final step) |
| <b>CYP11B2</b> | Aldosterone synthase | Aldosterone (Final step) |

- <b style="color:red">Cortisol Transport</b>: Cortisol circulates mostly bound to <i style="color:blue">Cortisol-Binding Globulin (CBG)</i> and albumin; only the free fraction is biologically active.
- <b style="color:red">11β-HSD1</b>: This enzyme converts inactive <i style="color:blue">cortisone</i> into active <i style="color:blue">cortisol</i> at the tissue level (prereceptor activation).
- <b style="color:red">11β-HSD2</b>: This enzyme inactivates cortisol to cortisone, primarily in the <i style="color:blue">kidneys</i>, to prevent cortisol from over-activating the mineralocorticoid receptor (MR).
- <b style="color:red">MR Affinity</b>: Cortisol and aldosterone bind the mineralocorticoid receptor (MR) with equal affinity, but cortisol circulates at 1000-fold higher concentrations, necessitating the protective role of 11β-HSD2.
- <b style="color:red">Aldosterone Mechanism</b>: In the kidney, aldosterone binds the MR to increase <i style="color:blue">ENaC</i> (epithelial sodium channel) expression, leading to sodium reabsorption, potassium excretion, and increased blood pressure.

### Cushing’s Syndrome (Glucocorticoid Excess)

- <b style="color:red">Iatrogenic Cushing's</b>: The <i style="color:blue">most common cause overall</i> of Cushing’s syndrome is the exogenous administration of glucocorticoids.
- <b style="color:red">Cushing’s Disease</b>: This specific term refers to Cushing’s syndrome caused by an <i style="color:blue">ACTH-producing pituitary adenoma</i> (the most common endogenous cause).
- <b style="color:red">ACTH-Dependent etiologies</b>: Includes Pituitary adenomas (75-80%) and <i style="color:blue">Ectopic ACTH secretion</i> (e.g., from bronchial or pancreatic carcinoids).
- <b style="color:red">ACTH-Independent etiologies</b>: Includes Adrenocortical adenomas, carcinomas, or nodular hyperplasia; characterized by <i style="color:blue">suppressed plasma ACTH</i>.
- <b style="color:red">Clinical Manifestations</b>: Classic features include <i style="color:blue">central obesity</i>, buffalo hump, moon facies, <i style="color:blue">broad purple striae</i> (>1 cm), easy bruising, proximal myopathy, and psychiatric symptoms (anxiety/depression).
- <b style="color:red">Hypokalemia in Cushing's</b>: Severe cortisol excess can overwhelm the 11β-HSD2 enzyme, leading to mineralocorticoid effects like <i style="color:blue">diastolic hypertension</i> and <i style="color:blue">hypokalemia</i> (common in ectopic ACTH).
- <b style="color:red">Screening Tests</b>: Diagnosis requires increased <i style="color:blue">24-hour urinary free cortisol (UFC)</i> (3 collections), failure of <i style="color:blue">Overnight Dexamethasone Suppression Test (1mg)</i>, or loss of diurnal rhythm (high <i style="color:blue">midnight salivary/serum cortisol</i>).
- <b style="color:red">Differentiating Etiology</b>: High-dose dexamethasone suppresses ACTH in Cushing's Disease but <i style="color:blue">not</i> in Ectopic ACTH or adrenal tumors.
- <b style="color:red">Inferior Petrosal Sinus Sampling (IPSS)</b>: The <i style="color:blue">gold standard</i> for distinguishing Cushing’s Disease from Ectopic ACTH when biochemical tests are inconclusive; a central-to-peripheral ACTH ratio >2 (baseline) or >3 (post-CRH) confirms a pituitary source.
- <b style="color:red">Surgical Treatment</b>: Transsphenoidal surgery is the first-line for Cushing’s Disease; unilateral adrenalectomy for adrenal adenomas.
- <b style="color:red">Medical Management</b>: Drugs like <i style="color:blue">Metyrapone</i>, <i style="color:blue">Ketoconazole</i>, and <i style="color:blue">Osilodrostat</i> (11β-hydroxylase inhibitors) are used to control cortisol synthesis.
- <b style="color:red">Adrenal Crisis Prevention</b>: Patients require glucocorticoid replacement therapy immediately following the removal of a cortisol-secreting tumor because the remaining HPA axis is chronically suppressed.

### Mineralocorticoid Excess (Hyperaldosteronism)

- <b style="color:red">Conn's Syndrome</b>: An aldosterone-producing adrenal adenoma causing primary hyperaldosteronism.
- <b style="color:red">Primary Aldosteronism (PA)</b>: The <i style="color:blue">most common cause of mineralocorticoid excess</i>; typically caused by bilateral micronodular hyperplasia or unilateral adenomas.
- <b style="color:red">Glucocorticoid-Remediable Aldosteronism (GRA)</b>: An autosomal dominant condition where a chimeric gene makes aldosterone synthesis <i style="color:blue">ACTH-dependent</i>; treated with low-dose dexamethasone.
- <b style="color:red">Liddle’s Syndrome</b>: A genetic "pseudoaldosteronism" caused by <i style="color:blue">constitutively active ENaC</i>; manifests with hypertension and hypokalemia but <i style="color:blue">low aldosterone</i>; treated with Amiloride.
- <b style="color:red">Clinical Hallmarks</b>: <i style="color:blue">Hypokalemic hypertension</i>, metabolic alkalosis, and increased cardiac remodeling. Note: 50% of PA patients may have normal potassium.
- <b style="color:red">Screening (ARR)</b>: The <i style="color:blue">Aldosterone-Renin Ratio (ARR)</i> is the screening test of choice. ARR >750 pmol/L per ng/mL/h with high aldosterone is positive.
- <b style="color:red">Medication Interference</b>: MR antagonists (Spironolactone) must be stopped <i style="color:blue">4 weeks</i> prior to ARR testing. Beta-blockers cause false positives; ACE inhibitors/ARBs cause false negatives.
- <b style="color:red">Confirmatory Tests</b>: Saline Infusion Test (failure of aldosterone to suppress <140 pmol/L) or Oral Sodium Loading.
- <b style="color:red">Adrenal Vein Sampling (AVS)</b>: Necessary in surgical candidates >40 years to distinguish unilateral adenoma (curable by surgery) from bilateral hyperplasia (treated medically). Lateralization is confirmed by an aldosterone/cortisol ratio 2x higher than the other side.
- <b style="color:red">Medical Treatment</b>: <i style="color:blue">Spironolactone</i> is the first-line MR antagonist; <i style="color:blue">Eplerenone</i> is a more selective alternative to avoid side effects like gynecomastia.

### Adrenal Masses and Carcinoma

- <b style="color:red">Adrenal Incidentaloma</b>: An incidentally discovered mass >1 cm requires evaluation for hormone autonomy and malignancy risk.
- <b style="color:red">Imaging Characteristics</b>: Adrenal <i style="color:blue">CT density <10–20 Hounsfield Units (HU)</i> suggests a lipid-rich benign adenoma. Malignant lesions are usually larger (>4 cm), inhomogeneous, and lobulated.
- <b style="color:red">Adrenocortical Carcinoma (ACC)</b>: A rare, highly aggressive malignancy; often presents with <i style="color:blue">mixed hormone excess</i> (cortisol + androgens). IGF2 overexpression is found in 90% of cases.

### Adrenal Insufficiency (Hypoadrenalism)

- <b style="color:red">Primary Adrenal Insufficiency (Addison’s Disease)</b>: Caused by destruction of the gland (most commonly <i style="color:blue">autoimmune adrenalitis</i>). It involves the loss of <i style="color:blue">both glucocorticoids and mineralocorticoids</i>.
- <b style="color:red">Secondary Adrenal Insufficiency</b>: Caused by HPA axis dysfunction (pituitary/hypothalamic tumors or iatrogenic steroid suppression). <i style="color:blue">Mineralocorticoid secretion is preserved</i> as it is regulated by RAAS.
- <b style="color:red">Hyperpigmentation</b>: A hallmark of <i style="color:blue">Primary</i> AI due to high ACTH levels stimulating melanocytes; found in skin creases, nipples, and oral mucosa.
- <b style="color:red">Adrenal Crisis</b>: An acute, life-threatening emergency presenting with <i style="color:blue">hypotension/shock</i>, abdominal pain, fever, and vomiting; often triggered by stress or infection.
- <b style="color:red">Diagnostic Gold Standard</b>: The <i style="color:blue">Short Cosyntropin (ACTH) Test</i>. A peak cortisol <450–500 nmol/L at 30–60 mins indicates insufficiency.
- <b style="color:red">Differentiating Primary vs. Secondary</b>: High ACTH + High Renin = <i style="color:blue">Primary</i>; Low/Normal ACTH = <i style="color:blue">Secondary</i>.
- <b style="color:red">Acute Treatment</b>: Immediate <i style="color:blue">IV saline rehydration</i> + <i style="color:blue">IV Hydrocortisone</i> (100 mg bolus, then 200 mg/24h).
- <b style="color:red">Chronic Maintenance</b>: Oral Hydrocortisone (15–25 mg in divided doses). Mineralocorticoid replacement (Fludrocortisone) is <i style="color:blue">only</i> required for Primary AI.
- <b style="color:red">Steroid Equipotency</b>: 1 mg Hydrocortisone = 0.2 mg Prednisolone = 0.25 mg Prednisone = 0.025 mg Dexamethasone.

### Congenital Adrenal Hyperplasia (CAH)

- <b style="color:red">21-Hydroxylase Deficiency</b>: Accounts for 90–95% of CAH cases; leads to <i style="color:blue">low cortisol</i> (causing high ACTH and adrenal hyperplasia) and <i style="color:blue">high androgens</i>.
- <b style="color:red">Classic CAH</b>: Presents in neonates; girls have ambiguous genitalia (virilization). <i style="color:blue">Salt-wasting form</i> includes mineralocorticoid deficiency, risking adrenal crisis.
- <b style="color:red">Diagnosis</b>: Elevated <i style="color:blue">17-hydroxyprogesterone (17OHP)</i> levels.
- <b style="color:red">Treatment Goals</b>: Replace cortisol to suppress ACTH and reduce excessive androgen production.

### Pheochromocytoma and Paraganglioma (PPGL)

- <b style="color:red">Pheochromocytoma Locations</b>: Pheochromocytomas arise from the adrenal medulla; Paragangliomas arise from extra-adrenal sympathetic or parasympathetic ganglia.
- <b style="color:red">Rule of 10s (Classic)</b>: 10% are bilateral, 10% are extra-adrenal, and 10% are metastatic (though move toward a genetic-based classification is modern).
- <b style="color:red">Classic Triad</b>: 1) Episodic headache, 2) Palpitations/tachycardia, and 3) Diaphoresis.
- <b style="color:red">Biochemical Testing</b>: Plasma and 24-hour urinary <i style="color:blue">fractionated metanephrines</i> are the most reliable markers (more sensitive than catecholamines).
- <b style="color:red">Clonidine Suppression Test</b>: Used if metanephrines are equivocal; clonidine fails to suppress normetanephrine in patients with pheochromocytoma.
- <b style="color:red">Histology</b>: Characteristic <i style="color:blue">Zellballen pattern</i> (nests of chief cells). Chief cells stain for <i style="color:blue">Chromogranin/Synaptophysin</i>; sustentacular cells stain for <i style="color:blue">S-100</i>.
- <b style="color:red">Pre-operative Management</b>: <i style="color:blue">Alpha-blockade FIRST</i> (e.g., Phenoxybenzamine) for 7–14 days, followed by beta-blockers only after adequate alpha-blockade to avoid a hypertensive crisis (unopposed alpha-stimulation).
- <b style="color:red">Pregnancy Management</b>: Tumor removal is best performed in the <i style="color:blue">fourth to sixth month</i> of gestation.

### Multiple Endocrine Neoplasia (MEN) Syndromes

- <b style="color:red">MEN 1 (Wermer’s)</b>: Triad of <i style="color:blue">3 Ps</i>: <i style="color:blue">Parathyroid</i> (90%, hyperplasia/adenoma), <i style="color:blue">Pancreatic NETs</i> (e.g., Gastrinoma, Insulinoma), and <i style="color:blue">Anterior Pituitary</i> adenomas (e.g., Prolactinoma). Gene: <i style="color:blue">MEN1</i> (Menin).
- <b style="color:red">Zollinger-Ellison Syndrome (ZES)</b>: Often caused by gastrinomas in MEN 1; presents with severe, recurrent peptic ulcers.
- <b style="color:red">MEN 2A (Sipple’s)</b>: Defined by <i style="color:blue">Medullary Thyroid Carcinoma (MTC)</i> (100%), <i style="color:blue">Pheochromocytoma</i> (50%), and <i style="color:blue">Parathyroid</i> hyperplasia (20%). Gene: <i style="color:blue">RET</i> (proto-oncogene).
- <b style="color:red">MEN 2B (MEN 3)</b>: Defined by <i style="color:blue">aggressive MTC</i>, <i style="color:blue">Pheochromocytoma</i>, mucosal neuromas (lips/tongue), and <i style="color:blue">Marfanoid habitus</i>. Note: <i style="color:blue">No parathyroid disease</i>. Gene: <i style="color:blue">RET</i> (specific codon 918 mutation).
- <b style="color:red">MEN 4</b>: MEN 1-like phenotype but caused by mutations in <i style="color:blue">CDKN1B (p27)</i>.
- <b style="color:red">Medullary Thyroid Carcinoma (MTC)</b>: Screening via <i style="color:blue">Serum Calcitonin</i>. Management involves prophylactic total thyroidectomy in RET-positive infants/children.
- <b style="color:red">Carney Complex</b>: Spotty skin pigmentation, cardiac myxomas, and PPNAD (periodic Cushing syndrome). Gene: <i style="color:blue">PRKAR1A</i>.
- <b style="color:red">McCune-Albright Syndrome</b>: Triad of polyostotic fibrous dysplasia, café-au-lait spots, and precocious puberty. Caused by a <i style="color:blue">postzygotic GNAS mutation</i> (mosaicism).

### Differential Diagnosis and Critical Comparisons

- <b style="color:red">Cushing Disease vs. Ectopic ACTH</b>: Cushing Disease (pituitary) usually shows suppression with high-dose dexamethasone and response to CRH; Ectopic ACTH shows neither and presents with very high ACTH and severe hypokalemia.
- <b style="color:red">Primary vs. Secondary Adrenal Insufficiency</b>: Primary (Addison’s) has hyperpigmentation and hyperkalemia (due to mineralocorticoid loss). Secondary has "alabaster" pale skin and normal potassium (intact mineralocorticoid axis).
- <b style="color:red">Primary vs. Secondary Aldosteronism</b>: Primary Aldosteronism has <i style="color:blue">Low Renin</i> (suppressed by high aldosterone). Secondary Aldosteronism (e.g., renal artery stenosis) has <i style="color:blue">High Renin</i> driving the aldosterone.
- <b style="color:red">PA vs. Liddle’s Syndrome</b>: Both present with hypokalemic hypertension. PA has high aldosterone/low renin; Liddle’s has <i style="color:blue">Low Aldosterone/Low Renin</i>.
- <b style="color:red">MEN 2A vs. MEN 2B</b>: Both have MTC and Pheo. MEN 2A has Hyperparathyroidism; MEN 2B has Neuromas/Marfanoid habitus and <i style="color:blue">no</i> parathyroid disease.
- <b style="color:red">11β-HSD1 vs. 11β-HSD2</b>: 11β-HSD1 <i style="color:blue">activates</i> (cortisone → cortisol) in many tissues. 11β-HSD2 <i style="color:blue">inactivates</i> (cortisol → cortisone) in the kidney to protect the MR.
- <b style="color:red">Hypokalemia in Cushing's vs. PA</b>: In PA, it's due to direct aldosterone action. In Cushing’s, it's due to excess cortisol overwhelming 11β-HSD2, activating the MR.
- <b style="color:red">Adrenal Adenoma vs. Carcinoma</b>: Adenomas are 1–2 cm, homogenous, and low HU (<10–20). Carcinomas are >4 cm, inhomogeneous, and often secrete multiple steroids (Cortisol + Androgens).
- <b style="color:red">Spironolactone vs. Eplerenone</b>: Spironolactone is a non-selective MR antagonist (causes gynecomastia). Eplerenone is selective and bypasses androgen/progesterone receptor interference.
- <b style="color:red">Primary vs. Secondary AI Potassium</b>: Hyperkalemia is a clue for <i style="color:blue">Primary</i> AI. Normal potassium is typical for <i style="color:blue">Secondary</i> AI.
- <b style="color:red">ACTH in AI</b>: ACTH is high in <i style="color:blue">Primary</i> AI (distinguishing skin darkening) and low/normal in <i style="color:blue">Secondary</i> AI.
- <b style="color:red">Cushing Screening Interference</b>: Biotin (interferes with assays); Estrogens/OCPs (elevate CBG, false positive Dexamethasone test); Antiepileptics (accelerate Dex metabolism).
- <b style="color:red">Pheo vs. Anxiety</b>: Pheochromocytoma paroxysms are usually shorter (<1 hr) and accompanied by significant hypertension, unlike standard panic attacks.
- <b style="color:red">MEN 1 vs. MEN 4</b>: Phenotypically identical, but MEN 1 involves the <i style="color:blue">menin</i> protein; MEN 4 involves the <i style="color:blue">p27</i> cell cycle inhibitor.
- <b style="color:red">Adrenal CT: Benign vs. Malignant</b>: Benign density is <20 HU; Malignant density is >20 HU and shows slow "washout" of contrast.
```

## QA
```text
### Adrenal Anatomy, Development, and Regulation

1. List the three layers of the <b style="color:red">Adrenal Cortex</b> from outer to inner. | 1) Zona glomerulosa <br>2) Zona fasciculata <br>3) Zona reticularis
2. What is the primary steroid produced by the <b style="color:red">Zona Glomerulosa</b>? | Mineralocorticoids (Aldosterone)
3. What is the primary steroid produced by the <b style="color:red">Zona Fasciculata</b>? | Glucocorticoids (Cortisol)
4. What is the primary steroid produced by the <b style="color:red">Zona Reticularis</b>? | Adrenal androgen precursors (DHEA)
5. What is the normal weight of a single <b style="color:red">Adult Adrenal Gland</b>? | 6–11 g
6. From which embryonic structure do the <b style="color:red">Adrenal Glands</b> originate? | Urogenital ridge
7. At what gestational week do the <b style="color:red">Adrenals</b> separate from the gonads and kidneys? | Sixth week
8. When does <b style="color:red">Fetal Steroidogenesis</b> of cortisol and DHEA begin? | Seventh to ninth weeks
9. Which axis regulates <b style="color:red">Cortisol and Adrenal Androgens</b>? | Hypothalamic-Pituitary-Adrenal (HPA) axis
10. Which hormones from the hypothalamus and pituitary regulate the <b style="color:red">HPA axis</b>? | CRH and ACTH
11. What are the primary regulators of <b style="color:red">Aldosterone</b> secretion? (2) | 1) RAAS (Renin-Angiotensin-Aldosterone System) <br>2) Serum potassium levels
12. Does the <b style="color:red">HPA Axis</b> primarily regulate mineralocorticoid secretion? | No. It is primarily regulated by RAAS and potassium.
13. Which cells release <b style="color:red">Renin</b> in response to decreased renal perfusion? | Juxtaglomerular cells
14. What enzyme converts <b style="color:red">Angiotensin I</b> to <b style="color:red">Angiotensin II</b>? | ACE (Angiotensin-Converting Enzyme)
15. Which receptor does <b style="color:red">Angiotensin II</b> bind to trigger aldosterone secretion? | AT1 receptor

### Steroid Hormone Synthesis and Action

16. What is the <b style="color:red">Rate-Limiting Step</b> in steroidogenesis? | Transport of cholesterol into mitochondria
17. Which protein facilitates the <b style="color:red">Rate-Limiting Step</b> of steroidogenesis? | StAR protein (Steroidogenic Acute Regulatory)
18. To which receptor does <b style="color:red">ACTH</b> bind in the adrenal cortex? | MC2R receptor
19. Which accessory protein is required for <b style="color:red">MC2R</b> trafficking? | MRAP
20. What second messengers are increased by <b style="color:red">ACTH Signaling</b>? | cAMP and PKA
21. What is the function of the enzyme <b style="color:red">CYP11A1</b>? | Side chain cleavage (Cholesterol to Pregnenolone)
22. Which enzyme converts <b style="color:red">Pregnenolone to Progesterone</b>? | 3β-HSD2
23. What is the dual function of the enzyme <b style="color:red">CYP17A1</b>? | 17α-hydroxylase and 17,20 lyase
24. Which enzyme performs <b style="color:red">21-hydroxylation</b> for cortisol and aldosterone? | CYP21A2
25. Which enzyme catalyzes the final step of <b style="color:red">Cortisol</b> synthesis? | CYP11B1 (11β-hydroxylation)
26. Which enzyme (aldosterone synthase) catalyzes the final step of <b style="color:red">Aldosterone</b> synthesis? | CYP11B2
27. To which proteins does <b style="color:red">Cortisol</b> mostly bind in circulation? (2) | 1) Cortisol-Binding Globulin (CBG) <br>2) Albumin
28. Which fraction of <b style="color:red">Circulating Cortisol</b> is biologically active? | Free fraction
29. What is the function of the enzyme <b style="color:red">11β-HSD1</b>? | Converts inactive cortisone to active cortisol
30. Where is <b style="color:red">11β-HSD2</b> primarily located? | Kidneys
31. What is the function of <b style="color:red">11β-HSD2</b> in the kidney? | Inactivates cortisol to cortisone
32. Why is <b style="color:red">11β-HSD2</b> necessary for the mineralocorticoid receptor (MR)? | Prevents cortisol from over-activating MR
33. Compare the affinity of <b style="color:red">Cortisol vs. Aldosterone</b> for the Mineralocorticoid Receptor (MR). | They have equal affinity
34. How much higher is the circulating concentration of <b style="color:red">Cortisol</b> compared to aldosterone? | 1000-fold higher
35. What channel expression is increased by <b style="color:red">Aldosterone</b> in the kidney? | ENaC (epithelial sodium channel)
36. What are the physiological effects of <b style="color:red">Aldosterone</b> on electrolytes and BP? (3) | 1) Sodium reabsorption <br>2) Potassium excretion <br>3) Increased blood pressure

### Cushing’s Syndrome (Glucocorticoid Excess)

37. What is the <b style="color:red">Most Common Cause Overall</b> of Cushing’s syndrome? | Exogenous glucocorticoid administration (Iatrogenic)
38. Define the term <b style="color:red">Cushing’s Disease</b>. | ACTH-producing pituitary adenoma
39. What are the <b style="color:red">ACTH-Dependent</b> etiologies of Cushing's? (2) | 1) Pituitary adenomas <br>2) Ectopic ACTH secretion
40. What are common sources of <b style="color:red">Ectopic ACTH</b>? | Bronchial or pancreatic carcinoids
41. What characterizes <b style="color:red">ACTH-Independent</b> Cushing's syndrome? | Suppressed plasma ACTH
42. List the common <b style="color:red">ACTH-Independent</b> etiologies of Cushing's. (3) | Adrenocortical adenomas, carcinomas, or nodular hyperplasia
43. List the classic clinical manifestations of <b style="color:red">Cushing’s Syndrome</b>. (6) | 1) Central obesity <br>2) Buffalo hump <br>3) Moon facies <br>4) Purple striae <br>5) Easy bruising <br>6) Proximal myopathy
44. What defines <b style="color:red">Purple Striae</b> in Cushing's syndrome? | Breadth greater than 1 cm
45. Why does <b style="color:red">Severe Cortisol Excess</b> cause hypokalemia? | Overwhelms 11β-HSD2; activates mineralocorticoid receptors
46. Which etiology of Cushing's is most associated with <b style="color:red">Hypokalemia and Diastolic Hypertension</b>? | Ectopic ACTH secretion
47. What are the recommended <b style="color:red">Screening Tests</b> for Cushing’s syndrome? (3) | 1) 24-hour UFC <br>2) Overnight Dexamethasone Suppression <br>3) Midnight salivary/serum cortisol
48. How many <b style="color:red">24-hour Urinary Free Cortisol (UFC)</b> collections are typically required? | Three collections
49. How does <b style="color:red">High-Dose Dexamethasone</b> affect ACTH in Cushing's Disease vs. Ectopic ACTH? | Suppresses in Cushing's Disease; no effect in Ectopic ACTH
50. What is the gold standard for distinguishing <b style="color:red">Cushing’s Disease</b> from Ectopic ACTH? | Inferior Petrosal Sinus Sampling (IPSS)
51. What <b style="color:red">IPSS Central-to-Peripheral ACTH Ratio</b> confirms a pituitary source? | >2 at baseline or >3 post-CRH
52. What is the first-line treatment for <b style="color:red">Cushing’s Disease</b>? | Transsphenoidal surgery
53. What is the treatment for <b style="color:red">Unilateral Adrenal Adenoma</b> causing Cushing's? | Unilateral adrenalectomy
54. Name three <b style="color:red">11β-Hydroxylase Inhibitors</b> used for medical management of Cushing's. | 1) Metyrapone <br>2) Ketoconazole <br>3) Osilodrostat
55. Why is <b style="color:red">Glucocorticoid Replacement</b> needed after removing a cortisol-secreting tumor? | Remaining HPA axis is chronically suppressed

### Mineralocorticoid Excess (Hyperaldosteronism)

56. Define <b style="color:red">Conn's Syndrome</b>. | Aldosterone-producing adrenal adenoma
57. What is the <b style="color:red">Most Common Cause</b> of mineralocorticoid excess? | Primary Aldosteronism (PA)
58. What are the two main causes of <b style="color:red">Primary Aldosteronism</b>? | 1) Bilateral micronodular hyperplasia <br>2) Unilateral adenomas
59. What is the genetic mechanism of <b style="color:red">Glucocorticoid-Remediable Aldosteronism (GRA)</b>? | Chimeric gene makes aldosterone synthesis ACTH-dependent
60. How is <b style="color:red">Glucocorticoid-Remediable Aldosteronism (GRA)</b> treated? | Low-dose dexamethasone
61. What is the cause of <b style="color:red">Liddle’s Syndrome</b>? | Constitutively active ENaC (genetic)
62. Describe the <b style="color:red">Aldosterone and Renin</b> levels in Liddle’s Syndrome. | Both low (Pseudoaldosteronism)
63. What is the treatment for <b style="color:red">Liddle’s Syndrome</b>? | Amiloride
64. List the <b style="color:red">Clinical Hallmarks</b> of Primary Aldosteronism. (3) | 1) Hypokalemic hypertension <br>2) Metabolic alkalosis <br>3) Cardiac remodeling
65. What percentage of patients with <b style="color:red">Primary Aldosteronism</b> have normal potassium? | 50 percent
66. What is the screening test of choice for <b style="color:red">Primary Aldosteronism</b>? | Aldosterone-Renin Ratio (ARR)
67. What <b style="color:red">ARR Value</b> is considered positive for Primary Aldosteronism? | >750 pmol/L per ng/mL/h
68. How long must <b style="color:red">MR Antagonists</b> be stopped before ARR testing? | Four weeks
69. How do <b style="color:red">Beta-Blockers</b> affect ARR testing? | Cause false positives
70. How do <b style="color:red">ACE inhibitors and ARBs</b> affect ARR testing? | Cause false negatives
71. List two <b style="color:red">Confirmatory Tests</b> for Primary Aldosteronism. | 1) Saline Infusion Test <br>2) Oral Sodium Loading
72. What result in the <b style="color:red">Saline Infusion Test</b> confirms Primary Aldosteronism? | Failure of aldosterone to suppress <140 pmol/L
73. When is <b style="color:red">Adrenal Vein Sampling (AVS)</b> necessary? | Surgical candidates >40 years old
74. What <b style="color:red">AVS Ratio</b> confirms lateralization in Primary Aldosteronism? | Aldosterone/cortisol ratio 2x higher than other side
75. Which <b style="color:red">Mineralocorticoid Receptor Antagonist</b> is first-line for medical treatment of PA? | Spironolactone
76. Why is <b style="color:red">Eplerenone</b> preferred over spironolactone in some patients? | Selective; avoids side effects like gynecomastia

### Adrenal Masses and Carcinoma

77. What size threshold defines an <b style="color:red">Adrenal Incidentaloma</b>? | Greater than 1 cm
78. What CT density in <b style="color:red">Hounsfield Units (HU)</b> suggests a benign adenoma? | <10–20 HU
79. What are the imaging characteristics of <b style="color:red">Malignant Adrenal Lesions</b>? (3) | 1) >4 cm <br>2) Inhomogeneous <br>3) Lobulated
80. How does <b style="color:red">Adrenocortical Carcinoma (ACC)</b> often present hormonal-wise? | Mixed hormone excess (Cortisol + Androgens)
81. Which factor is overexpressed in 90% of <b style="color:red">ACC</b> cases? | IGF2

### Adrenal Insufficiency (Hypoadrenalism)

82. What is the most common cause of <b style="color:red">Primary Adrenal Insufficiency</b>? | Autoimmune adrenalitis (Addison’s Disease)
83. Which hormones are lost in <b style="color:red">Primary Adrenal Insufficiency</b>? | Both glucocorticoids and mineralocorticoids
84. What causes <b style="color:red">Secondary Adrenal Insufficiency</b>? | HPA axis dysfunction (tumors or steroid suppression)
85. Why is <b style="color:red">Mineralocorticoid Secretion</b> preserved in secondary AI? | Regulated by RAAS, not the pituitary
86. Why does <b style="color:red">Hyperpigmentation</b> occur in Primary AI? | High ACTH levels stimulate melanocytes
87. Where is <b style="color:red">Hyperpigmentation</b> classically found in Addison’s? (3) | 1) Skin creases <br>2) Nipples <br>3) Oral mucosa
88. List the clinical presentation of an <b style="color:red">Adrenal Crisis</b>. (4) | 1) Hypotension/shock <br>2) Abdominal pain <br>3) Fever <br>4) Vomiting
89. What is the diagnostic gold standard for <b style="color:red">Adrenal Insufficiency</b>? | Short Cosyntropin (ACTH) Test
90. What peak cortisol value indicates AI in a <b style="color:red">Short Cosyntropin Test</b>? | <450–500 nmol/L at 30–60 mins
91. Compare <b style="color:red">ACTH and Renin</b> in Primary vs. Secondary AI. | Primary: High ACTH + High Renin; Secondary: Low/Normal ACTH
92. What is the <b>Acute Treatment</b> for an <b style="color:red">Adrenal Crisis</b>? | IV saline rehydration + IV Hydrocortisone (100 mg bolus)
93. What is the <b>Chronic Maintenance</b> dose for Oral Hydrocortisone? | 15–25 mg in divided doses
94. Which type of AI requires <b style="color:red">Fludrocortisone</b> replacement? | Primary Adrenal Insufficiency only
95. 1 mg of <b style="color:red">Hydrocortisone</b> is equivalent to how much Prednisolone? | 0.2 mg
96. 1 mg of <b style="color:red">Hydrocortisone</b> is equivalent to how much Dexamethasone? | 0.025 mg

### Congenital Adrenal Hyperplasia (CAH)

97. What enzyme deficiency causes 90-95% of <b style="color:red">CAH</b> cases? | 21-Hydroxylase Deficiency
98. What are the hormonal results of <b style="color:red">21-Hydroxylase Deficiency</b>? | Low cortisol and High androgens
99. How does <b style="color:red">Classic CAH</b> present in newborn girls? | Ambiguous genitalia (virilization)
100. What additional deficiency is found in the <b style="color:red">Salt-Wasting Form</b> of CAH? | Mineralocorticoid deficiency
101. What is the primary diagnostic marker for <b style="color:red">CAH</b>? | Elevated 17-hydroxyprogesterone (17OHP)
102. What are the main <b style="color:red">Treatment Goals</b> for CAH? | Replace cortisol to suppress ACTH and reduce androgens

### Pheochromocytoma and Paraganglioma (PPGL)

103. Where do <b style="color:red">Pheochromocytomas</b> arise? | Adrenal medulla
104. Where do <b style="color:red">Paragangliomas</b> arise? | Extra-adrenal sympathetic or parasympathetic ganglia
105. State the <b style="color:red">Rule of 10s</b> for pheochromocytoma. (3) | 1) 10% bilateral <br>2) 10% extra-adrenal <br>3) 10% metastatic
106. List the <b style="color:red">Classic Triad</b> of pheochromocytoma symptoms. | 1) Episodic headache <br>2) Palpitations <br>3) Diaphoresis
107. Which biochemical tests are most reliable for <b style="color:red">PPGL</b>? | Plasma and 24-hour urinary fractionated metanephrines
108. When is a <b style="color:red">Clonidine Suppression Test</b> used? | If metanephrines are equivocal
109. Describe the characteristic <b style="color:red">Histology</b> of pheochromocytoma. | Zellballen pattern (nests of chief cells)
110. What do <b style="color:red">Chief Cells and Sustentacular Cells</b> stain for in PPGL? | Chief: Chromogranin/Synaptophysin; Sustentacular: S-100
111. What is the correct <b>Pre-operative Sequence</b> for PPGL? | Alpha-blockade first, then Beta-blockers
112. Why must <b style="color:red">Alpha-blockade</b> precede beta-blockade in PPGL? | To avoid hypertensive crisis from unopposed alpha-stimulation
113. When is the best time for <b style="color:red">PPGL Tumor Removal</b> during pregnancy? | Fourth to sixth month of gestation

### Multiple Endocrine Neoplasia (MEN) Syndromes

114. List the <b style="color:red">3 Ps</b> of MEN 1 (Wermer’s). | 1) Parathyroid <br>2) Pancreatic NETs <br>3) Anterior Pituitary
115. Which gene is mutated in <b style="color:red">MEN 1</b>? | MEN1 (Menin)
116. What syndrome causes recurrent peptic ulcers in <b style="color:red">MEN 1</b>? | Zollinger-Ellison Syndrome (Gastrinoma)
117. List the components of <b style="color:red">MEN 2A (Sipple’s)</b>. (3) | 1) Medullary Thyroid Carcinoma <br>2) Pheochromocytoma <br>3) Parathyroid hyperplasia
118. Which gene/protein is mutated in <b style="color:red">MEN 2 (A and B)</b>? | RET (proto-oncogene)
119. List the components of <b style="color:red">MEN 2B</b>. (4) | 1) Aggressive MTC <br>2) Pheo <br>3) Mucosal neuromas <br>4) Marfanoid habitus
120. Is <b style="color:red">Parathyroid Disease</b> present in MEN 2B? | No
121. What gene is mutated in <b style="color:red">MEN 4</b>? | CDKN1B (p27)
122. How is <b style="color:red">Medullary Thyroid Carcinoma (MTC)</b> screened? | Serum Calcitonin
123. Define <b style="color:red">Carney Complex</b> findings. | Spotty pigmentation, cardiac myxomas, PPNAD
124. What are the three components of <b style="color:red">McCune-Albright Syndrome</b>? | Polyostotic fibrous dysplasia, café-au-lait spots, precocious puberty
125. What is the genetic cause of <b style="color:red">McCune-Albright Syndrome</b>? | Postzygotic GNAS mutation (mosaicism)

### Differential Diagnosis and Critical Comparisons

126. Contrast <b style="color:red">Cushing Disease vs. Ectopic ACTH</b> response to High-dose Dex. | Disease: Suppresses; Ectopic: No suppression
127. Contrast <b style="color:red">Primary vs. Secondary AI</b> skin color. | Primary: Hyperpigmentation; Secondary: "Alabaster" pale skin
128. Contrast <b style="color:red">Primary vs. Secondary Aldosteronism</b> renin levels. | Primary: Low Renin; Secondary: High Renin
129. How do you distinguish <b style="color:red">Primary Aldosteronism from Liddle’s Syndrome</b>? | PA: High Aldosterone; Liddle’s: Low Aldosterone
130. Contrast <b style="color:red">11β-HSD1 vs. 11β-HSD2</b> function. | 11β-HSD1: Activates (cortisone to cortisol); 11β-HSD2: Inactivates (cortisol to cortisone)
131. Contrast <b style="color:red">Adrenal Adenoma vs. Carcinoma</b> size and HU. | Adenoma: 1-2 cm, homogenous, <20 HU; Carcinoma: >4 cm, inhomogeneous, >20 HU
132. Compare <b style="color:red">Primary vs. Secondary AI</b> potassium levels. | Primary: Hyperkalemia; Secondary: Normal potassium
133. Contrast <b>Pheochromocytoma Paroxysms</b> with Panic Attacks. | Pheo: shorter (<1 hr) with significant hypertension
134. Contrast <b>MEN 1 vs. MEN 4</b> protein involvement. | MEN 1: menin; MEN 4: p27 cell cycle inhibitor
135. Contrast <b>Benign vs. Malignant</b> Adrenal CT Washout. | Benign: Fast washout; Malignant: Slow washout
```


# 12
## Summary


## QA



